Document:

AMENDED AND RESTATED SERVICES AGREEMENT

 Exhibit 4.18 

AMENDED AND RESTATED SERVICES AGREEMENT 

AMENDED AND RESATED SERVICES AGREEMENT (this “Agreement”), dated as of November 1, 2009 (the “Effective
Date”), by and between Evotec AG, a company incorporated under the laws of Germany (“Evotec AG”), Evotec (UK) Ltd., a company incorporated under the laws of England (“Evotec UK” and, together with Evotec
AG, “Evotec”), and CHDI Foundation, Inc., a New Jersey corporation (the “Foundation”). Evotec AG, Evotec UK and the Foundation shall hereinafter be referred to individually as a “Party” and
collectively as the “Parties”. 
 The Foundation’s mission is to rapidly discover and develop drugs that
delay or slow the progression of Huntington’s disease. 
 Evotec AG has expertise in (a) the fields of assay
development, reagent development, compound screening, compound profiling and compound receipt, handling, storage and distribution and (b) providing services related thereto. 

Evotec UK has expertise in (a) the fields of structural biology and chemical synthesis, including compound design, parallel
synthesis, solution and solid phase chemistry, computational chemistry, preparation of libraries of chemical compounds and compound procurement, receipt, handling, storage and distribution and (b) providing services related thereto. 

The Foundation and Evotec entered into that certain Services Agreement (the “Services Agreement”), dated as of
January 1, 2008 (the “Original Effective Date”), pursuant to which the Foundation engaged Evotec to provide certain services relating to, among other things, (a) assay development, reagent development, compound screening
and compound profiling, (b) structural biology and chemical synthesis, including compound design, parallel synthesis, solution and solid phase chemistry, computational chemistry and the preparation of libraries of compounds, (c) compound
procurement and (d) compound receipt, handling, storage and distribution. 
 The Foundation and Evotec desire to amend and
restate the Services Agreement in its entirety. 
 In consideration of the mutual representations, warranties and covenants
contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

Definitions 
  

	1.	Definitions. For the purposes of this Agreement, the following terms have the meanings set forth below: 

 

	 	(a)	“ADMET Services” means the activities undertaken by Evotec under this Agreement to perform in vivo, in vitro and in silico tests relating
to Adsorption, Distribution, Metabolism, Excretion and Toxicology of the Evotec Library Compounds and/or Services Compounds. 

 

	 	(b)	“Analytical Chemistry Services” means the activities undertaken by Evotec under this Agreement to perform NMR structural elucidation (including isotope
and cosy noesy), purification chiral and achiral testing (including HPLC, prep HPLC and SFC* HPLC), mass spectrometry testing (including HRMS and FT MS), microanalysis and other analytical testing and analytical method development and testing.

  

	 	(c)	“Assay” means an assay to detect the interaction of a Target with a Compound. 

 

 1 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	(d)	 “Assay Development Services” means the activities undertaken by Evotec under this Agreement to (i) to develop, validate or
optimize an Assay or (ii) to adapt an Assay to the EVOscreen® Technology, the
OperaTM Technology or other state-of-the-art technology. 

 

	 	(e)	“Assay Development Services Intellectual Property” means any Intellectual Property conceived, discovered, invented, made or first reduced to practice
in the course of Evotec’s performance of the Assay Development Services that does not constitute Evotec Background Intellectual Property or Foundation Background Intellectual Property. For the avoidance of any doubt, Assay Development Services
Intellectual Property shall not include any Intellectual Property that constitutes Evotec Background Intellectual Property or Foundation Background Intellectual Property. 

 

	 	(f)	“Bankruptcy Event” means the (i) making of a general assignment for the benefit of creditors by an entity; (ii) filing of any petition by an
entity or the commencement of any proceeding voluntarily by an entity for any relief under any bankruptcy or insolvency laws or any law relating to the relief of debtors; (iii) consent by an entity to the entry of an order in an involuntary
bankruptcy or insolvency case; (iv) entry of an order or decree for relief against an entity by a court of competent jurisdiction in an involuntary case under any bankruptcy or insolvency laws or any law relating to the relief of debtors, which
order or decree is unstayed and in effect for a period of sixty (60) consecutive days; (v) appointment, with or without the consent of an entity, of any receiver, liquidator, custodian, assignee, trustee, sequestrator or other similar
official of an entity or any substantial part of its property; or (vi) admission by an entity in writing of its inability to pay its debts generally as they become due. 

 

	 	(g)	“Biology Services” means the activities undertaken by Evotec under this Agreement to provide biology services which services shall include the Assay
Development Services, Profiling Services, Reagent Development Services and Screening Services. 

  

	 	(h)	“Biology Services FTE” means an FTE that has been designated to perform Biology Services. 

 

	 	(i)	“Biology Services Intellectual Property” means any Intellectual Property conceived, discovered, invented, made or first reduced to practice in the
course of Evotec’s performance of the Biology Services (other than the Assay Development Services) that does not constitute Evotec Background Intellectual Property, Assay Development Services Intellectual Property or Foundation Background
Intellectual Property. For the avoidance of any doubt, Biology Services Intellectual Property shall not include any Intellectual Property that constitutes Evotec Background Intellectual Property, Assay Development Services Intellectual Property or
Foundation Background Intellectual Property. 

  

	 	(j)	“CHD” means the applications and databases developed by the Foundation to enable the Foundation and Evotec to manage the Foundation’s Compound
libraries, including CHD Registration, Compound receipt and distribution and Compound inventory control and tracking. 

  

	 	(k)	“CHD Registered Compound” means any Services Compound for which CHD Registration has been completed. 

 

	 	(l)	“CHD Registration” means the process by which information about a Services Compound is entered into CHD as described in the CHD Registration Protocol.

  

	 	(m)	“CHD Registration Protocol” means the written description attached hereto as Exhibit 1 (or any amendment thereof set forth in the applicable
Steering Committee meeting minutes) setting forth the specific activities and procedures to be conducted to complete the CHD Registration of a Services Compound. 

 

 2 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	(n)	“CHD Registration Services” means the activities undertaken by Evotec under this Agreement to complete the CHD Registration of an Evotec Synthesized
Compound in accordance with Section 3(c)(ii) of this Agreement and the CHD Registration Protocol. 

  

	 	(o)	“Compound” means a discrete chemical entity. 

  

	 	(p)	“Compound Data” means, with respect to each Services Compound, the information to be provided by Evotec relating to such Services Compound as described
in Appendix A or as otherwise specified by the Foundation’s Services Manager (as defined in Section 7(b)(i) of this Agreement) and set forth in the applicable Steering Committee (as defined in Section 7(a)(i) of
this Agreement) meeting minutes to the extent such information (i) results from Evotec’s performance of the Services and (ii) is in the possession or control of Evotec. Such Compound Data shall include (A) an MDL structure-data
(sd) file and (B) analytical data (LCMS and NMR) for each Compound as set forth in Appendix A. 

  

	 	(q)	“Compound Management Services” means the CHD Registration Services, Compound Receipt, Handling and Storage Services and Stored Compound Distribution
Services. 

  

	 	(r)	“Compound Management Services FTE” means an FTE that has been designated to perform Compound Management Services. 

 

	 	(s)	“Compound Procurement Services” means the activities undertaken by Evotec under this Agreement to procure commercially available Compounds in
accordance with the specifications set forth in Appendix A or as otherwise specified by the Foundation’s Services Manager and set forth in the Steering Committee meeting minutes. 

 

	 	(t)	“Compound Purification Services” means the activities undertaken by Evotec under this Agreement to purify (i) Evotec Procured Compounds;
(ii) Evotec Synthesized Compounds; or (iii) Foundation Provided Compounds, in each case to the required purity as described in Appendix A or as otherwise specified by the Foundation’s Services Manager and set forth in the
applicable Steering Committee meeting minutes. 

  

	 	(u)	“Compound Receipt, Handling and Storage Services” means the activities undertaken by Evotec under this Agreement to receive, handle (e.g., conducting
quality control tests, plating and replating, etc.) and store a CHD Registered Compound (including a Stored Compound) in accordance with Section 3(c)(iii) of this Agreement and the Compound Receipt, Handling and Storage Services Protocol
specified in CHD for such CHD Registered Compound. 

  

	 	(v)	“Compound Receipt, Handling and Storage Services Protocols” means (a) the written description attached hereto as Exhibit 2 and
(b) such other written descriptions set forth in the applicable Steering Committee meeting minutes, in each case setting forth the specific activities and procedures to be conducted by Evotec in the performance of the conduct of the Compound
Receipt, Handling and Storage Services. 

  

	 	(w)	“Compound Specifications” means, with respect to each Services Compound, the specifications relating to such Services Compound as described in
Appendix A or as otherwise specified by the Foundation’s Services Manager and set forth in the applicable Steering Committee meeting minutes. 

  

	 	(x)	“Compound Synthesis Services” means the activities undertaken by Evotec under this Agreement to perform synthetic services to synthesize Compounds at
the laboratory scale, including the Analytical Chemistry Services and Computational Chemistry Services in accordance with the specifications set forth in Appendix A or as otherwise specified by the Foundation’s Services Manager and set
forth in the applicable Steering Committee meeting minutes. 

  

 3 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	(y)	“Computational Chemistry Services” means the activities undertaken by Evotec under this Agreement to perform activities utilizing one or more of the
following technologies: (i) physical chemical property calculations (an application of in silico models for physical chemical properties, including quantum mechanical and machine learning techniques); (ii) bioinformatics (sequence
alignment, homology modeling and selectivity profiling); (iii) molecular modeling (structure based design which includes docking of vendor and in silico libraries, molecular mechanics and dynamics and scoring of virtuals hits);
(iv) ligand based design (rationalization of SAR, molecular overlays, conformation analysis, and pharmacophore development and 3D searching techniques); (v) compound library design (in silico reagent/monomer optimization and
selection, prioritization of compounds for synthesis); (vi) QSAR (QSAR techniques, including COMFA and COMSIA); (vii) diversity analysis and clustering techniques; and (viii) application using neural networks model classification.

  

	 	(z)	“Confidential Information” means (i) the terms and conditions of this Agreement and (ii) all information (A) provided by one Party (the
“Disclosing Party”) to another Party (the “Receiving Party”) that is clearly identified as “Confidential” by the Disclosing Party at the time of disclosure or (B) specifically deemed to be
“Confidential Information” pursuant to Section 11(c)(i) of this Agreement. If such transmittal occurs orally, the Disclosing Party will promptly reduce such transmittal to writing, mark and identify it as confidential, and
provide such record to the Receiving Party. Specifically excepted from Confidential Information is all information that: (1) was previously known by the Receiving Party other than by reason of disclosure by the Disclosing Party; (2) is
publicly disclosed either prior to or subsequent to the Receiving Party’s receipt of such information except by breach of this Agreement; (3) is rightfully received by the Receiving Party from a third party without an obligation of
confidence to the Disclosing Party; or (4) is independently developed by the Receiving Party without use or reliance upon Confidential Information provided by the Disclosing Party. 

 

	 	(aa)	 “Evotec Background Intellectual Property” means (i) all Intellectual Property (A) owned or licensed by Evotec as of the
Original Effective Date (including the EVOscreen®Technology, the FCS+plus Technology, the Miniaturization
Technology or the OperaTM Technology) or (B) acquired or licensed by Evotec from a third party (other than
the Foundation) after the Original Effective Date; (ii) all Intellectual Property conceived, discovered, invented, made or first reduced to practice by, or on behalf of, Evotec on or after the Original Effective Date other than in the course of
Evotec’s performance of the Services; and (iii) all improvements, variations, modifications or enhancements of the Intellectual Property described in (i) and (ii) above conceived, discovered, invented, made or first reduced to
practice by, or on behalf of, Evotec after the Original Effective Date that does not constitute Foundation Background Intellectual Property (including any such improvements, variations, modifications or enhancements conceived, discovered, invented,
made or first reduced to practice by, or on behalf of, Evotec in the course of Evotec’s performance of the Services). For the avoidance of any doubt, Evotec Background Intellectual Property shall include (1) any Intellectual Property
described in (i), (ii) or (iii) above that is employed by Evotec in the course of Evotec’s performance of the Services and (2) any Intellectual Property in respect of the Evotec Library Compounds. 

 

	 	(bb)	“Evotec Library Compounds” means the Compounds that constitute the Evotec Libraries. 

 

	 	(cc)	“Evotec Customer” means those third parties to whom Evotec provides services in the ordinary course of its business. 

 

	 	(dd)	“Evotec Libraries” means the screening libraries of Compounds maintained by Evotec. 

 

	 	(ee)	“Evotec Medicinal Chemistry Intellectual Property” means any Intellectual Property conceived, discovered, invented, made or first reduced to practice
in the course of Evotec’s performance of the 

  

 4 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	
Medicinal Chemistry Services that (i) is employed by Evotec in the course of Evotec’s performance of the Medicinal Chemistry Services, including chemical synthesis tools, chemical
design tools, structural biology tools, analytical tools, automation tools, software, computational chemistry tools (including modelling tools, and virtual libraries) and purification tools and (ii) is not necessary or useful for the synthesis,
manufacture, distribution or sale of any Services Compound. 

  

	 	(ff)	“Evotec Procured Compound” means the physical sample of any Compound physically procured by Evotec in the course of Evotec’s performance of the
Compound Procurement Services and delivered to the Foundation or a Foundation Collaborator (including Evotec). 

  

	 	(gg)	“Evotec Provided Materials” means the physical samples of Evotec Procured Compounds, raw materials, reagents, cell lines and other materials and
supplies acquired by Evotec from a third party to enable Evotec to perform the Services. 

  

	 	(hh)	“Evotec Provided Reimbursable Materials” means those physical samples of unique or exceptionally high-cost Evotec Provided Materials which are
specified in the applicable Steering Committee meeting minutes as Evotec Provided Materials for which the Foundation is required, subject to Section 5(a) and Section 8(c)(i) of this Agreement, to reimburse Evotec.

  

	 	(ii)	“Evotec Purified Compound” means the physical sample of any Services Compound physically purified by Evotec in the course of Evotec’s performance
of the Compound Purification Services. 

  

	 	(jj)	“Evotec Synthesized Compound” means the physical sample of any Compound physically synthesized by Evotec in the course of Evotec’s performance of
the Compound Synthesis Services and delivered to the Foundation or a Foundation Collaborator (including Evotec). The Parties hereby agree that any Compound which is derived computationally but is not physically synthesized in the course of
Evotec’s performance of the Compound Synthesis Services shall not constitute an Evotec Synthesized Compound. 

  

	 	(kk)	 “EVOscreen®
 Technology” means the high throughput screening technology as described in Part 1 of Appendix B. 

  

	 	(ll)	“FCS+plus Technology” means the fluorescence spectroscopy technology as described in Part 2 of Appendix B. 

 

	 	(mm)	“Foundation Background Intellectual Property” means (i) all Intellectual Property (including Intellectual Property relating to any Foundation
Provided Materials) (A) owned or licensed by the Foundation as of the Original Effective Date or (B) acquired or licensed by the Foundation from a third party (other than Evotec) after the Original Effective Date; (ii) all
Intellectual Property conceived, discovered, invented, made or first reduced to practice by, or on behalf of, the Foundation after the Original Effective Date (other than in the course of Evotec’s performance of the Services); and
(iii) all improvements, variations, modifications or enhancements of the Intellectual Property described in (i) and (ii) above conceived, discovered, invented, made or first reduced to practice by, or on behalf of, the Foundation
after the Original Effective Date (including any such improvements, variations, modifications or enhancements conceived, discovered, invented, made or first reduced to practice by, or on behalf of, Evotec in the course of Evotec’s performance
of the Services). 

  

	 	(nn)	“Foundation Collaborators” means those third parties to whom the Foundation grants the right to use all or part of the Assay Development Services
Intellectual Property, Services Deliverables (including Stored Compounds), Services Intellectual Property or Services Results (including Stored Compounds) for HD Research and Development, including any entity collaborating with the Foundation in the
conduct of HD Research and Development and/or fee for service laboratories providing services to the Foundation in the furtherance of the Foundation’s conduct of HD Research and Development. 

 

 5 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	(oo)	“Foundation Provided Compound” means the physical sample of any (i) Compound provided to Evotec by, or on behalf of, the Foundation to enable
Evotec to perform the Services (any such Compound to be specified by the Foundation’s Services Manager and set forth in the applicable Steering Committee meeting minutes) and (ii) Services Compound which constitutes a Stored Compound.

  

	 	(pp)	“Foundation Provided Compound Information” means all information relating to a Foundation Provided Compound provided to Evotec by, or on behalf of, the
Foundation to enable Evotec to perform the Services (any such information to be specified (i) by the Foundation’s Services Manager and set forth in the applicable Steering Committee meeting minutes or (ii) in CHD).

  

	 	(qq)	“Foundation Provided Material” means (i) the physical sample of any cell line, reagent and other material other than a Compound (e.g., Target
proteins) provided to Evotec by, or on behalf of, the Foundation to enable Evotec to perform the Services (any such items to be specified by the Foundation’s Services Manager and set forth in the applicable Steering Committee meeting minutes)
or (ii) any Foundation Provided Compound. 

  

	 	(rr)	“Foundation Provided Material Information” means (i) in the case of any Foundation Provided Material that does not constitute a Foundation
Provided Compound, all information relating to such Foundation Provided Material that is provided to Evotec by, or on behalf of, the Foundation (any such information to be specified by the Foundation’s Services Manager and set forth in the
applicable Steering Committee meeting minutes) or (ii) in the case of any Foundation Provided Material that constitutes a Foundation Provided Compound, all Foundation Provided Compound Information in respect of such Foundation Provided
Compound. 

  

	 	(ss)	“Foundation Provided Methods and Processes” means any methods or processes provided to Evotec provided to Evotec by, or on behalf of, the Foundation to
enable Evotec to perform the Services (any such method or process to be specified by the Foundation’s Services Manager and set forth in the applicable Steering Committee meeting minutes). 

 

	 	(tt)	“Foundation Provided Services Information” means all information provided to Evotec by, or on behalf of, the Foundation to enable Evotec to perform the
Services (any such information to be specified by the Foundation’s Services Manager and set forth in the applicable Steering Committee meeting minutes). 

 

	 	(uu)	“FTE” means the equivalent of a full-time scientist employed by Evotec working an aggregate of two hundred twenty (220) days per annum.

  

	 	(vv)	“HD Research and Development” means any activity useful for the creation, development, manufacture or distribution of a product or service for the
diagnosis, treatment, cure or prevention of Huntington’s disease other than (i) the manufacture or distribution of any such product or service for sale or (ii) the sale of any such product or service. For the avoidance of doubt, HD
Research and Development shall not include any right to (A) manufacture or distribute any such product or service for sale or (B) sell any such product or service. 

 

	 	(ww)	“Hit” means an Evotec Library Compound or a Services Compound identified during the performance of the Screening Services as interacting with a Target
in accordance with the activity criteria specified by the Foundation’s Services Manager and set forth in the applicable Steering Committee meeting minutes that is further confirmed as being active through the performance of the Profiling
Services. 

  

	 	(xx)	“Intellectual Property” means any discovery, invention, formulation, know-how, method, technological development, enhancement, modification,
improvement, work of authorship, computer 

  

 6 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	
software (including, but not limited to, source code and executable code) and documentation thereof, data or collection of data, whether patentable or not, or susceptible to copyright or any
other form of legal protection. 

  

	 	(yy)	“Medicinal Chemistry Services” means the activities undertaken by Evotec under this Agreement to provide medicinal chemistry services which services
shall include the ADMET Services, Analytical Chemistry Services, Compound Synthesis Services, Compound Procurement Services, Compound Purification Services, Computational Chemistry Services and Structural Biology Services. 

 

	 	(zz)	“Medicinal Chemistry Services FTE” means an FTE that has been designated to perform Medicinal Chemistry Services. 

 

	 	(aaa)	“Medicinal Chemistry Services Intellectual Property” means any Intellectual Property conceived, discovered, invented, made or first reduced to practice
in the course of Evotec’s performance of the Medicinal Chemistry Services or Compound Management Services that does not constitute Evotec Background Intellectual Property, Evotec Medicinal Chemistry Intellectual Property or Foundation
Background Intellectual Property. 

  

	 	(bbb)	“Miniaturisation Technology” means the assay miniaturisation technology as described in Part 3 of Appendix B. 

 

	 	(ccc)	
“OperaTM Technology” means
the imaging technology as described in Part 4 of Appendix B. 

  

	 	(ddd)	“Profiling Services” means the activities undertaken by Evotec under this Agreement to characterize Evotec Library Compounds and/or Services Compounds
that interact with a Target (including selectivity testing, concentration response testing and potentially in vivo efficacy studies as agreed by the JSC). 

 

	 	(eee)	“Project” means each specific program of Services to be performed by Evotec. 

 

	 	(fff)	“Reagent Development Services” means the activities undertaken by Evotec under this Agreement to develop reagents (including labeling, cloning,
recombinant cell and protein production (such as protein expression and purification of Target material). 

  

	 	(ggg)	“Screening Services” means the activities undertaken by Evotec under this Agreement to identify whether Evotec Library Compounds and/or Services
Compounds interact with the Target. Screening Services under this Agreement shall be limited to screens for up to a total of ten thousand (10,000) Evotec Library Compounds and/or Services Compounds per screen. 

 

	 	(hhh)	“Services” means the Biology Services together with the Compound Management Services and Medicinal Chemistry Services. 

 

	 	(iii)	“Services Compound” means any (i) Evotec Procured Compound, (ii) Evotec Purified Compound, (iii) Evotec Synthesized Compound or
(iv) Foundation Provided Compound. 

  

	 	(jjj)	“Services Deliverable” means (i) the Services Results; (ii) each Project Report (as defined in Section 7(e) of this Agreement);
and (iii) any other products or items specified by the Foundation Services Manager, mutually agreed in the Steering Committee meetings and set forth in the applicable Steering Committee minutes which are made or produced in the performance of
the Services; provided, however, Services Deliverables shall not include any product or item that constitute Evotec Background Intellectual Property or Evotec Medicinal Chemistry Intellectual Property. For the avoidance of doubt, Services
Deliverables shall not include any products or items that constitute Evotec Background Intellectual Property or Evotec Medicinal Chemistry Intellectual Property. 

 

 7 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	(kkk)	“Services FTE” means the Biology Services FTEs together with the Compound Management Services FTEs and Medicinal Chemistry Services FTEs.

  

	 	(lll)	“Services Intellectual Property” means the Biology Services Intellectual Property together with the Medicinal Chemistry Services Intellectual Property.

  

	 	(mmm)	“Services Results” means all data, formulae, information, materials, methods, outcomes, protocols, specimens, or other results or work product
(regardless of how documented or recorded) developed, made or produced in the course of Evotec’s performance of the Services, including (i) any Services Compounds, (ii) any Compound Data and Compound Specifications related to any
Services Compound and (iii) any Structures, in each case developed, made or produced by Evotec in the course of Evotec’s performance of the Services. For the avoidance of any doubt, Services Results shall not include any Assay Development
Services Intellectual Property, Evotec Background Intellectual Property, Evotec Medicinal Chemistry Intellectual Property or Foundation Background Intellectual Property. The Parties hereby agree that any Compound which is derived computationally but
is not physically synthesized in the course of Evotec’s performance of the Services shall not constitute Services Results. 

  

	 	(nnn)	“Stored Compound” means any CHD Registered Compound for which Evotec has completed the initial Compound Receipt, Handling and Storage Services.

  

	 	(ooo)	“Stored Compound Distribution Order” means a notification from the Foundation to Evotec through CHD to distribute one or more Stored Compounds to the
Foundation Collaborator as specified in CHD. 

  

	 	(ppp)	“Stored Compound Distribution Services” means the activities undertaken by Evotec under this Agreement to distribute a Stored Compound in accordance
with Section 3(c)(iv) of this Agreement and the Stored Compound Distribution Services Protocol specified in the Stored Compound Distribution Order for such Stored Compound. 

 

	 	(qqq)	“Stored Compound Distribution Services Protocols” means (a) the written description attached hereto as Exhibit 2 and (b) such other
written descriptions set forth in the applicable Steering Committee meeting minutes, in each case setting forth the specific activities and procedures to be conducted by Evotec in the performance of the conduct of the Stored Compound Distribution
Services. 

  

	 	(rrr)	“Structural Biology Services” means the activities undertaken by Evotec under this Agreement to elucidate Structures which activities may include one
or more of the following: (i) protein engineering; (ii) protein production (including protein construct design, molecular biology, protein expression in bacteria, insect and mammalian cell lines); (iii) protein purification;
(iv) protein characterization (including Western blot, SDS PAGE and mass spectroscopy); (v) protein ligand binding analysis (including thermal shift of protein melting point, CD, NMR and ITC); (vi) protein crystallization (including
apo protein and protein complexes); (vii) protein crystal mounting; (viii) protein crystal diffraction data analysis (in-house data collection and management of synchrotron data collection); and (ix) protein structure elucidation and
refinement. 

  

	 	(sss)	“Structure” means the three dimensional structure of crystallized proteins or complexes of proteins and Compounds as characterized preferably by X-ray
diffraction studies. 

  

	 	(ttt)	“Specialized Third Party Licenses and Services” means, with respect to each Project, those (i) specialized third party licenses which are
necessary for Evotec to possess and use a unique technology, methodology, process, reagent, cell line, compound or other material to perform the Services as agreed upon by the Steering Committee (any such agreement to be set forth in the

  

 8 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	
applicable Steering Committee meeting minutes) or (ii) specialized services to be performed by a third party which are necessary to enable Evotec to perform the Services in the conduct of
such Project as agreed upon by the Steering Committee (any such agreement to be set forth in the applicable Steering Committee meeting minutes). 

  

	 	(uuu)	“Target” means a biological target specified by the Foundation’s Services Manager and set forth in the applicable Steering Committee meeting
minutes to be used in the performance of the Services. 

  

	 	(vvv)	“Term” means the period specified in Section 14(a) of this Agreement. 

Services 
  

	2.	Number of Services FTEs; Designation of the Services FTEs; Initial Designation of the Foundation Designated Services FTEs; Re-Designation of the Foundation
Designated Services FTEs; Increases in the Number of Services FTEs; Reductions in the Number of Services FTEs; Replacement of Services FTEs. 

  

	 	(a)	Number of Services FTEs; Designation of the Services FTEs; Initial Designation of the Foundation Designated Services FTEs; Re-Designation of the Foundation
Designated Services FTEs. 

  

	 	(i)	Number of Services FTEs. During the Term, Evotec shall provide forty nine (49) Services FTEs to perform the Services. 

 

	 	(ii)	Designation of the Services FTEs. The Parties hereby agree that (A) ten and a half (10.5) of the Services FTEs shall be designated as Biology Services
FTEs on a permanent basis (the “Permanent Biology Services FTEs”); (B) twenty-three and a half (23.5) of the Services FTEs shall be designated as Medicinal Chemistry Services FTEs on a permanent basis (the
“Permanent Medicinal Chemistry Services FTEs”); (C) one (1.0) of the Services FTEs shall be designated as a Compound Management Services FTE on a permanent basis (the “Permanent Compound Management Services
FTE”); and (D) fourteen (14.0) of the Services FTEs shall from time to time, upon the request and at the direction of the Foundation, be designated as either Biology Services FTEs, Compound Management Services FTEs or Medicinal
Chemistry Services FTEs (the “Foundation Designated Services FTEs”). 

  

	 	(iii)	Initial Designation of the Foundation Designated Services FTEs; Re-Designation of the Foundation Designated Services FTEs. As of the Effective Date, the Parties
hereby agree that (A) eight (8.0) of the Foundation Designated Services FTEs shall be designated as Biology Services FTEs, (B) three (3.0) of the Foundation Designated Services FTEs shall be designated as Compound Management
Services FTEs and (C) three (3.0) of the Foundation Designated Services FTEs shall be designated as Medicinal Chemistry Services FTEs. The Parties hereby agree that, at any time and from time to time after the Effective Date, the
Foundation Services Manager shall have the right to re-designate each Foundation Designated Services FTE as either a Biology Services FTEs, Compound Management Services FTEs or Medicinal Chemistry Services FTEs by providing written (including via
email) notice to the Evotec Services Manager specifying the number of Foundation Designated Services FTE to be designated as Biology Services FTEs, Compound Management Services FTEs and Medicinal Chemistry Services FTEs. Upon the receipt of any such
request, Evotec hereby agrees to re-designate the Foundation Designated Services FTE as directed in such notice as soon as reasonably possible but in any event within twenty (20) business days of the receipt of such notice.

  

	 	(b)	Increases in the Number of Services FTEs. The number of Services FTEs may only be increased upon (A) the submission by the Steering Committee to each of
Evotec and the Foundation of a recommendation to increase the number of Services FTEs (which recommendation shall specify the 

  

 9 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	
type of Services FTE (e.g. Permanent Biology Services FTEs, Permanent Medicinal Chemistry Services FTEs or Foundation Designated Services FTEs) to be increased) and (B) the execution by an
authorized signatory of each of Evotec and the Foundation of a written amendment to this Agreement adopting the recommendation of the Steering Committee to increase the number of Services FTEs. The Parties hereby agree that any increase in the
number of Services FTEs (1) shall not occur until a date that is after the date upon which both Evotec and the Foundation have agreed in writing to increase the number of Services FTEs and (2) shall occur within a period of time as agreed
upon by the Steering Committee. 

  

	 	(c)	Reductions in the Number of Services FTEs. 

  

	 	(i)	Services FTE Reduction Notices. If the Foundation desires to reduce the number of Services FTEs, the Foundation shall, during each 30-day rolling period, have
the right to reduce the number of Services FTEs by providing written notice (each, a “Services FTE Reduction Notice”) to Evotec to such effect; provided, however, the Foundation shall only have the right to deliver one Services FTE
Reduction Notice during any such 30-day rolling period. Each Services FTE Reduction Notice shall specify the number and type of Services FTEs (e.g. Permanent Biology Services FTEs, Permanent Medicinal Chemistry Services FTEs or Foundation Designated
Services FTE) to be reduced. The Foundation hereby acknowledges that (A) a reduction in the number of Services FTEs by the Foundation in accordance with this Section 2(c) may affect the time frames for the delivery of the Services
Deliverables and Services Results to be delivered by Evotec and (B) the Monthly Services Payment (as defined in Section 8(d)(i) of this Agreement) in respect of any Services FTE reduced in accordance with this
Section 2(c) shall be due until the date on which such Services FTE is reduced for all purposes of this Agreement. 

  

	 	(ii)	Reduction in the Number of Services FTEs to Twenty (20) Services FTEs. If the number of Services FTEs on the date the Foundation delivers a Services FTE
Reduction Notice to Evotec (such number to be determined using only those Services FTEs that are not the subject of a previously delivered Services FTEs Reduction Notice) is greater than twenty (20), the timing with respect to the reduction of the
number Services FTEs shall be as provided in (A) and (B) below: 

  

	 	(A)	If the number of Services FTEs specified in the Services FTE Reduction Notice is less than or equal to five (5), the number of Services FTEs shall be reduced by the
number specified in the Services FTE Reduction Notice on the date that is thirty (30) days following the date such Services FTE Reduction Notice is received by Evotec. 

 

	 	(B)	If the number of Services FTEs specified in the Services FTE Reduction Notice is greater than five (5), the number of Services FTEs shall be reduced by the number
specified in the Services FTE Reduction Notice as follows: (1) the number of Services FTEs shall be reduced by five (5) on the date that is thirty (30) days following the date such Services FTE Reduction Notice is received by Evotec
and (2) the number of Services FTEs shall be reduced by a number equal to the number specified in the Services FTE Reduction Notice minus five (5) on the date that is ninety (90) days following the date such Services FTE
Reduction Notice is received by Evotec. 

  

	 	(iii)	Reduction in the Number of Services FTEs below Twenty (20) Services FTEs. If the number of Services FTEs on the date the Foundation delivers a Services FTE
Reduction Notice to Evotec (such number to be determined using only those Services FTEs that are not the subject of a previously delivered Services FTEs Reduction Notice) is less than or equal twenty (20), (A) the number of Services FTEs
specified in the Services FTE Reduction Notice may not exceed a number (such number to be rounded to the nearest whole number greater than zero) that is ten percent (10%) of the then current number of Services FTEs (excluding any Services FTEs
subject to a previously delivered Services FTE Reduction Notice) and (B) the number of Services FTEs 

  

 10 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	
shall be reduced for all purposes of this Agreement by the number specified in the Services FTE Reduction Notice on the date that is thirty (30) days following the date such Services FTE
Reduction Notice is received by Evotec. 

  

	 	(d)	Replacement of Services FTEs. Upon the written request of the Foundation, Evotec shall, in a reasonable period of time following such request, replace any
Services FTE performing the Services identified by the Foundation. 

  

	3.	Performance of the Services; Utilization of the Services FTEs; Limited Right to Subcontract Services; Additional Agreements Related to the Performance of the
Compound Procurement Services; Reimbursement for Compounds Procured by Evotec During the Performance of the Compound Procurement Services; 

  

	    	Additional Agreements Related to the Performance of the Compound Management Services. 

 

	 	(a)	Performance of the Services; Utilization of the Services FTEs; Limited Right to Subcontract Services. 

 

	 	(i)	Performance of the Services. Evotec hereby agrees to (A) perform the Services in accordance with this Agreement as requested by the Foundation’s
Services Managers in respect of each Project (including completing the activities agreed upon by the Steering Committee in respect of each Project within the estimated time frames agreed upon by the Steering Committee for such Project);
(B) provide the number of Services FTEs required by this Agreement to perform the Services in accordance with this Agreement and as agreed upon by the Steering Committee; and (C) devote such other resources (including all necessary
physical space and facilities, equipment, tools, materials and supplies) and effort as is necessary to perform the Services in accordance with this Agreement and as agreed upon by the Steering Committee. Evotec hereby further agrees that all
Services FTEs shall be supported by staff with expertise in biology, medicinal and synthetic organic chemistry, molecular modelling, computational chemistry, purification, analysis, polymer chemistry, automation science, data management, project
management and other areas as may be necessary for Evotec’s performance of the Services and its other obligations under this Agreement. Notwithstanding the foregoing, Evotec shall not be obligated to perform Services requested by the
Foundation’s Services Manager to the extent that Evotec (1) does not have the technical capabilities, equipment and/or third party Intellectual Property rights to perform such requested Services and (2) is not performing such
requested Services on its own behalf or on behalf of any third party. In the event Evotec declines to provide a Service requested by the Foundation’s Services Manager for any of the reasons set forth in the preceding sentence, Evotec shall,
promptly following the request for such Service by the Foundation’s Services Manager, deliver a written notice to the Foundation setting forth a description of the Service that it is unable to provide together with detailed information relating
to the reason(s) (e.g., technical capabilities, equipment and/or third party Intellectual Property Rights) Evotec has declined to perform such requested Services. Evotec shall promptly notify the Foundation’s Services Managers if Evotec
determines that Evotec will not be able to continue to conduct or complete in a timely manner any of the Services Evotec has not declined to provide under this Agreement. 

 

	 	(ii)	Utilization of the Services FTEs. Evotec hereby agrees that (A) each Services FTE (or fractional unit thereof) shall devote one-hundred percent
(100%) of his or her effort to performing the Services; (B) no Services FTE (or fractional unit thereof) shall, unless expressly permitted pursuant to Section 8(b)(ii) of this Agreement, perform the Compound Purification
Services; and (C) no Services FTE (or fractional unit thereof) shall provide services of any type or nature to Evotec or any third party (other than the Foundation). 

 

	 	(iii)	Limited Right to Subcontract Services. With respect to the performance of the Services, the Parties hereby acknowledge and agree that Evotec may
(A) sub-contract those activities which are 

  

 11 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	
(1) agreed upon by the Steering Committee and (2) set forth and identified in the applicable Steering Committee meeting minutes as activities to be sub-contracted and
(B) sub-contract such designated activities to the third party agreed upon by the Steering Committee and identified in the applicable Steering Committee meeting minutes (each such third party hereinafter referred to as a
“Subcontractor”). Evotec hereby agrees that (A) each Subcontractor shall agree in writing to conduct such activities in accordance with, and subject to, terms and conditions equivalent to those of this Agreement and
(B) Evotec shall cause each Subcontractor to conduct such activities in accordance with, and subject to, terms and conditions equivalent to those of this Agreement. Evotec hereby further agrees that Evotec shall be solely responsible and liable
for the activities conducted by each Subcontractor as if such activities were conducted by Evotec. 

  

	 	(b)	Additional Agreements Related to the Performance of the Compound Procurement Services; Reimbursement for Compounds Procured by Evotec During the Performance of the
Compound Procurement Services. 

  

	 	(i)	General. Evotec shall perform the Compound Procurement Services in accordance with Section 3(a) of this Agreement and this Section 3(b).

  

	 	(ii)	Additional Agreements Related to the Performance of the Compound Procurement Services. Evotec shall only perform the Compound Procurement Services in respect of
a Compound that has been (A) agreed upon by the Steering Committee and (B) set forth and identified (together with the estimated cost to procure such Compound) in the applicable Steering Committee meeting minutes, in each case as Compounds
to be procured by Evotec under this Agreement. Evotec shall not, without the prior written consent of the Steering Committee, procure any Compound to be procured by Evotec during the course of the performance by Evotec of the Compound Procurement
Services under this Agreement if the cost to procure such Compound from a third party is greater than 110% of the estimated cost to procure such Compound as agreed upon by the Steering Committee and set forth in the applicable Steering Committee
meeting minutes. 

  

	 	(iii)	Reimbursement for Compounds Procured by Evotec During the Performance of the Compound Procurement Services. Subject to Section 3(b)(ii) of this
Agreement, the Foundation shall, in accordance with Section 8(c)(i) of this Agreement, reimburse Evotec for the actual costs incurred by Evotec to procure any Evotec Procured Compound. 

 

	 	(c)	Additional Agreements Related to the Performance of the Compound Management Services. 

 

	 	(i)	General. Evotec shall perform the Compound Management Services in accordance with Section 3(a) of this Agreement and this Section 3(c).

  

	 	(ii)	CHD Registration. 

  

	 	(A)	CHD Registration by Evotec. Evotec shall perform the CHD Registration Services in respect of each Evotec Synthesized Compound as requested by the
Foundation’s Services Managers. 

  

	 	(B)	CHD Registration by the Foundation. The Foundation shall be responsible for initiating and completing the CHD Registration in respect of each Evotec Procured
Compound and Foundation Provided Compound. 

  

	 	(iii)	Compound Receipt, Handling and Storage Services. 

  

	 	(A)	General. Evotec shall perform the Compound Receipt, Handling and Storage Services in respect of each CHD Registered Compound which is (1) received by Evotec
or (2) otherwise in the possession of Evotec (i.e., Stored Compounds), in each case in accordance with the Compound Receipt, Handling and Storage Services Protocol applicable to such CHD 

 

 12 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	
Registered Compound. Evotec hereby agrees that Evotec shall not perform the Compound Receipt, Handling and Storage Services in respect of any Services Compound received by, or otherwise in the
possession of, Evotec until the CHD Registration for such Services Compound has been completed. 

  

	 	(B)	Stored Compounds Deemed Foundation Provided Materials. For the avoidance of any doubt, the Parties hereby acknowledge and agree that each Stored Compound shall
be deemed a “Foundation Provided Material” for all purposes of this Agreement. 

  

	 	(iv)	Stored Compound Distribution Services. 

  

	 	(A)	General. Evotec shall perform the Stored Compound Distribution Services in respect of each Stored Compound that is the subject of a Stored Compound Distribution
Order in accordance with the Stored Compound Distribution Services Protocol as specified in such Stored Compound Distribution Order. Evotec hereby agrees that Evotec shall not perform the Stored Compound Distribution Services in respect of any
(1) Services Compound received by, or otherwise in the possession of, Evotec that is not a Stored Compound or (2) Stored Compound that is not the subject of a Stored Compound Distribution Order. 

 

	 	(B)	Distributed Stored Compounds Deemed Services Deliverables; Transfer of Title, Delivery and Transport of Stored Compounds. For the avoidance of any doubt, the
Parties hereby acknowledge and agree that each Stored Compound distributed by Evotec pursuant to this Section 3(c)(iv) shall be (1) deemed “Services Deliverables” for all purposes of this Agreement and (2) shipped to
the delivery point specified in the Stored Compound Distribution Order for such Stored Compound (CIF or CIP, as applicable) (Incoterms 2000). Title to, and all risk of loss in, each Stored Compound distributed by Evotec pursuant to a Stored Compound
Distribution Order shall pass to the Foundation upon the delivery of such Stored Compound to the delivery point specified in such Stored Compound Distribution Order. 

 

	 	(v)	Notices Related to Non-Conforming Compounds; Withdrawal of Stored Compounds. 

 

	 	(A)	Notices Related to Non-Conforming Compounds. If, in the course of performing the Compound Management Services, Evotec determines that a CHD Registered Compound
or Stored Compound (1) does not meet the stated specificiations for such CHD Registered Compound or Stored Compound (e.g., an Evotec Procured Compound is determined to not meet the quality, purity or quantity specifications specified in the
order for such Evotec Procured Compound) or (2) is contaminated, damaged, defective or of an insufficient quantity to enable Evotec to properly perform the Compound Management Services in respect thereof, Evotec shall promptly (x) cease
the performance of the Compound Management Services in respect of such CHD Registered Compound or Stored Compound and (y) provide notice to the Foundation identifying such CHD Registered Compound or Stored Compound and setting forth the details
of such determination. 

  

	 	(B)	Withdrawal of Stored Compounds. In the event the Foundation desires to withdraw a Stored Compound from being subject to this Agreement, the Foundation shall
deliver a written notice (each, a “Stored Compound Withdrawal Notice”) to Evotec setting forth the following information: (1) the unique Foundation Compound identification number and, as applicable, batch number for such Stored
Compound; (2) a statement that such Stored Compound is to be withdrawn as a “Stored Compound” for purposes of this Agreement; and (3) instructions directing Evotec to either (x) appropriately discard or destroy such Stored
Compound or 

  

 13 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	
(y) ship such Stored Compound to the Foundation or to such third party as specified in such Stored Compound Withdrawal Notice. Evotec hereby agrees that upon the receipt of a Stored Compound
Withdrawal Notice by Evotec, Evotec shall, as directed in such Stored Compound Withdrawal Notice, immediately discard or destroy or ship the Stored Compound that is the subject of such Stored Compound Withdrawal Notice. Evotec further agrees that
any Stored Compound that is the subject of a Stored Compound Withdrawal Notice shall no longer be deemed a “Stored Compound” for purposes of this Agreement immediately upon, as applicable, the delivery of such Stored Compound to the
delivery point specified in such Stored Compound Withdrawal Notice or at the time such Stored Compound is either discarded or destroyed. 

  

	4.	Obligation to Provide Foundation Provided Materials and Foundation Provided Material Information; Use and Ownership of Foundation Provided Material
Information and Foundation Provided Materials; Retention of Foundation Provided Materials; Risk of Loss of Foundation Provided Materials; Transfer of Foundation Provided Materials Upon any Termination of this Agreement; Use and Ownership of
Foundation Provided Methods and Processes and Foundation Provided Services Information. 

  

	 	(a)	Obligation to Provide Foundation Provided Materials and Foundation Provided Material Information; Use and Ownership of Foundation Provided Material Information and
Foundation Provided Materials; Retention of Foundation Provided Materials. 

  

	 	(i)	Obligation to Provide Foundation Provided Materials and Foundation Provided Material Information. The Foundation shall be responsible for all aspects of
acquiring and providing to Evotec sufficient amounts of the Foundation Provided Materials together with the Foundation Provided Material Information. The Foundation hereby represents and warrants that the Foundation shall have the right to transfer,
or cause to be transferred, to Evotec for the purposes of performing the Services all such Foundation Provided Materials and Foundation Provided Material Information. The Foundation hereby further represents and warrants that all such Foundation
Provided Materials and Foundation Provided Material Information provided to Evotec by, or at the direction of, the Foundation will be provided to Evotec in compliance with all applicable federal, state, local and international laws, rules,
regulations, orders and guidelines. 

  

	 	(ii)	Use and Ownership of Foundation Provided Materials and Foundation Provided Material Information. Evotec hereby agrees that the Foundation Provided Materials and
the Foundation Provided Material Information (A) shall be used by Evotec for the sole purpose of performing the Services under this Agreement and for no other purpose and (B) shall not be transferred to any third party except (1) as
expressly required or contemplated by this Agreement (e.g., to a Subcontractor in accordance with Section 3(a)(iii) of this Agreement or to a third party pursuant to a Stored Compound Distribution Order) or (2) pursuant to the
written request of the Foundation. Except to the extent required to enable Evotec to perform the Services, Evotec hereby further agrees that it will not, directly or indirectly, reverse engineer, deconstruct or in any way analyze or determine the
identity, structure or composition of any Foundation Provided Materials or the properties thereof (chemical, biochemical, physical, biological or other). Evotec hereby acknowledges and further agrees that (x) as between Evotec and the
Foundation, the Foundation owns the Foundation Provided Materials and Foundation Provided Material Information and (y) Evotec shall have no ownership or other interest in any Foundation Provided Materials or Foundation Provided Material
Information. 

  

 14 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	(iii)	Retention of Foundation Provided Materials. 

  

	 	(A)	Retention of Foundation Provided Materials that do not Constitute Stored Compounds. Evotec shall retain all unused Foundation Provided Materials that do not
constitute Stored Compounds (all such Foundation Provided Materials hereinafter referred to as “Non-Stored Compound Foundation Provided Materials”) for a period (each, a “Non-Stored Compound Foundation Provided Materials
Retention Period”) of one hundred and eighty (180) days following the completion of the Services for which such Non-Stored Compound Foundation Provided Materials were provided. During each Non-Stored Compound Foundation Provided
Materials Retention Period, Evotec shall, at the Foundation’s request and expense, ship all or part of the unused Non-Stored Compound Foundation Provided Materials subject to such Non-Stored Compound Foundation Provided Materials Retention
Period to the Foundation or to such third party as the Foundation shall direct in writing. Upon the expiration of the Non-Stored Compound Foundation Provided Materials Retention Period in respect of a Non-Stored Compound Foundation Provided
Material, Evotec shall, subject to providing the Foundation with thirty (30) days prior written notice, appropriately discard or destroy all such unused Non-Stored Compound Foundation Provided Materials. The Foundation hereby acknowledges and
agrees that in the event that a Non-Stored Compound Foundation Provided Material is provided to Evotec on behalf of the Foundation under separate agreement between a third party and Evotec, such agreement may require the return of such Non-Stored
Compound Foundation Provided Material to such third party. 

  

	 	(B)	Retention of Foundation Provided Materials that Constitute Stored Compounds. Except as expressly contemplated or permitted by this Agreement, Evotec shall,
subject to the terms of this Agreement, store and maintain all unused Foundation Provided Materials that constitute Stored Compounds (all such Foundation Provided Materials hereinafter referred to as “Stored Compound Foundation Provided
Materials”) indefinitely. The Foundation hereby acknowledges and agrees that in the event that a Stored Compound Foundation Provided Material is provided to Evotec on behalf of the Foundation under separate agreement between a third party
and Evotec, such agreement may require the return of such Stored Compound Foundation Provided Material to such third party. 

  

	 	(iv)	Transfer of Foundation Provided Materials Upon any Termination of this Agreement. Upon any termination of this Agreement, Evotec shall, at the cost and expense
of the Foundation, (A) continue to store, handle and maintain all unused Foundation Provided Materials in accordance with the applicable terms of this Agreement (even if such terms have been terminated in accordance with
Section 14(d)(i) of this Agreement) and (B) at the written request(s) of the Foundation, ship all or part of the unused Foundation Provided Materials to the Foundation or to such third party as specified in each such written
request. The Foundation hereby acknowledges and agrees that in the event that a Foundation Provided Material is provided to Evotec on behalf of the Foundation under separate agreement between a third party and Evotec, such agreement may require the
return of such Foundation Provided Material to such third party. 

  

	 	(v)	Risk of Loss of Foundation Provided Materials. Evotec hereby agrees to assume, and shall be responsible for, all risk of loss in or associated with (A) the
receipt, handling and storage of any Foundation Provided Material and (B) the preparation for shipment and shipment of any Foundation Provided Material beginning immediately upon the delivery of such Foundation Provided Material to Evotec by,
or at the direction of, the Foundation and continuing until such Foundation Provided Material is delivered to the delivery point specified by the Foundation. 

  

 15 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	(b)	Use and Ownership of Foundation Provided Methods and Processes and Foundation Provided Services Information. To the knowledge of the Foundation (after due
inquiry and investigation), the Foundation has the right to transfer and deliver, or cause to be transferred and delivered, to Evotec for use in the performance of the Services all Foundation Provided Methods and Processes and Foundation Provided
Services Information. Evotec hereby agrees that the Foundation Provided Methods and Processes and Foundation Provided Services Information (i) shall be used by Evotec for the sole purpose of performing the Services under this Agreement and for
no other purpose and (ii) shall not be transferred to any third party except (A) as expressly required or contemplated by this Agreement (e.g., to a Subcontractor in accordance with Section 3(a)(iii) of this Agreement) or
(B) pursuant to the written request of the Foundation. Evotec hereby acknowledges and further agrees that (1) as between Evotec and the Foundation, the Foundation owns the Foundation Provided Methods and Processes and Foundation Provided
Services Information and (2) Evotec shall have no ownership or other interest in any Foundation Provided Methods and Processes or Foundation Provided Services Information. 

 

	5.	Reimbursement for Evotec Provided Reimbursable Materials; Use and Ownership of Evotec Provided Reimbursable Materials; Retention of Evotec Provided Reimbursable
Materials. 

  

	 	(a)	Reimbursement for Evotec Provided Reimbursable Materials. Evotec hereby acknowledges and agrees that no Evotec Provided Material shall be deemed an Evotec
Provided Reimbursable Material unless (i) the designation of such Evotec Provided Material as an Evotec Provided Reimbursable Material was agreed upon by the Steering Committee and (ii) such designation (together with the estimated cost to
procure such Evotec Provided Material) is set forth in the applicable Steering Committee meeting minutes. Evotec hereby agrees that it shall not, without the prior consent of the Steering Committee (which consent shall be set forth in the applicable
Steering Committee meeting minutes), procure any Evotec Provided Reimbursable Material if the actual cost to procure any such Evotec Provided Reimbursable Material is more than 110% of the estimated cost of such Evotec Provided Reimbursable Material
as set forth in the applicable Steering Committee meeting minutes. Subject to the foregoing, the Foundation shall, in accordance with this Section 5(a) and Section 8(c)(ii) of this Agreement, reimburse Evotec for the actual
costs incurred by Evotec to procure any Evotec Provided Reimbursable Materials. 

  

	 	(b)	Use and Ownership of Evotec Provided Reimbursable Materials; Retention of Evotec Provided Reimbursable Materials. Evotec hereby agrees that the Evotec Provided
Reimbursable Materials (i) shall be used by Evotec for the sole purpose of performing the Services and for no other purpose and (ii) shall not be transferred to any third party except (A) as expressly required or contemplated by this
Agreement (e.g., to a Subcontractor in accordance with Section 3(a)(iii) of this Agreement) or (B) pursuant to the written request of the Foundation. Evotec hereby acknowledges and further agrees that (1) as between Evotec and
the Foundation, the Foundation owns the Evotec Provided Reimbursable Materials and (2) Evotec shall have no ownership or other interest in any Evotec Provided Reimbursable Materials. Evotec shall retain all unused Evotec Provided Reimbursable
Materials for a period (each, an “Evotec Provided Reimbursable Materials Retention Period”) of one hundred and eighty (180) days following the completion of the activities under this Agreement for which such Evotec Provided
Reimbursable Materials were provided. During each Evotec Provided Reimbursable Materials Retention Period, Evotec shall, at the Foundation’s request and expense, ship all or part of the unused Evotec Provided Reimbursable Materials subject to
such Evotec Provided Reimbursable Materials Retention Period to the Foundation or to such third party as the Foundation shall direct in writing. Upon the expiration of such Evotec Provided Reimbursable Materials Retention Period, Evotec shall
appropriately discard or destroy all such unused Evotec Provided Reimbursable Materials. 

  

 16 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	(c)	Transfer of Evotec Provided Reimbursable Materials Upon any Termination of this Agreement. Upon any termination of this Agreement, Evotec shall, at the cost and
expense of the Foundation, (i) continue to store, handle and maintain all unused Evotec Provided Reimbursable Materials in accordance with the applicable terms of this Agreement (even if such terms have been terminated in accordance with
Section 14(d)(i) of this Agreement) and (ii) at the written request(s) of the Foundation, ship all or part of the unused Evotec Provided Reimbursable Materials to the Foundation or to such third party as specified in each such
written request. 

  

	 	(d)	Risk of Loss of Evotec Provided Reimbursable Materials. Evotec hereby agrees to assume, and shall be responsible for, all risk of loss in or associated with
(i) the receipt, handling and storage of any Evotec Provided Reimbursable Material and (ii) the preparation for shipment and shipment of any Evotec Provided Reimbursable Material beginning immediately upon the delivery of such Evotec
Provided Reimbursable Material to Evotec and continuing until such Evotec Provided Reimbursable Material is delivered to the delivery point specified by the Foundation. 

 

	6.	Reimbursement for Specialized Third Party Licenses and Services; Reimbursement for Synchrotron Data Collection. 

 

	 	(a)	Reimbursement for Specialized Third Party Licenses and Services. The Foundation shall, in accordance with this Section 6(a) and
Section 8(c)(iii) of this Agreement, reimburse Evotec for the actual costs incurred by Evotec to license or procure any Specialized Third Party Licenses and Services (including any associated royalty costs paid by Evotec to any licensor
for the agreed use of such license which are based upon Evotec’s revenues generated from the use of such license); provided, that, (i) the Steering Committee has agreed to Evotec licensing or procuring such Specialized Third Party Licenses
and Services (any such agreement to be set forth in the applicable Steering Committee meeting minutes) and (ii) the terms and conditions (including cost) upon which such Specialized Third Party Licenses and Services are to be licensed or
procured have been approved in writing by the Foundation. 

  

	 	(b)	Reimbursement for Synchrotron Data Collection. The Foundation shall, in accordance with this Section 6(b) and Section 8(c)(iv) of this
Agreement, reimburse Evotec for the actual costs incurred by Evotec to for data collection related to the performance of Structural Biology Services requiring synchrotron data collection; provided, that, the Steering Committee has agreed to Evotec
conducting such synchrotron data collection activities (any such agreement to be set forth in the applicable Steering Committee meeting minutes). 

Services/Project Management 
  

	7.	Establishment of the Steering Committee; Responsibilities of the Steering Committee; Operating Procedures of the Steering Committee; Decision by Steering Committee;
Steering Committee Minutes; Appointment of the Services Managers; Responsibilities of the Services Managers; Appointment of the Project Managers; Responsibilities of the Project Managers; Limited Authority of the Steering Committees, Services
Managers and Project Managers; Project Reports; Recordkeeping. 

  

	 	(a)	Establishment of the Steering Committee; Responsibilities of the Steering Committee; Operating Procedures of the Steering Committee; Decision by Steering Committee;
Steering Committee Minutes. 

  

	 	(i)	Establishment of the Steering Committee. The Parties hereby agree to establish within a reasonable period of time following the date hereof a committee to
oversee the performance of the Services (the “Steering Committee”). The Steering Committee shall be comprised of four (4) members, two (2) of which members shall be designated by each Party (one of which shall be

  

 17 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	
each Party’s Biology Services Manager and one of which shall be each Parties Medicinal Chemistry Services Manager (as defined in Section 7(b)(i) of this Agreement). Each Party
may request the attendance of other non-voting personnel to the Steering Committee meetings. 

  

	 	(ii)	Responsibilities of the Steering Committee. The Steering Committee shall, among other things, (A) develop and define the description and scope of each
Project (including setting forth the number of Services FTEs to be designated to complete each such Project and the estimated timeframe to complete each such Project); (B) approve the number of Services FTEs to be designated to complete each
such Project and the estimated timeframe to complete each such Project; (C) for each Project, approve the initial costs (and subsequent changes requested by the Project Managers) related to (1) Evotec Provided Reimbursable Materials,
(2) Specialized Third Party Licenses and Services and (3) data collection related to the performance of Structural Biology Services requiring synchrotron data collection required for such Project in respect of each such Project;
(D) oversee the coordination, implementation and performance of the Services in respect of the Projects; (E) review the status and progress of the Projects; (F) determine if changes are needed to the number of Services FTEs under this
Agreement and submit any such changes to the Parties for consideration and approval; (G) review and discuss the Services Deliverables, Services Results and such other matters related to this Agreement and the Services as requested by either of
the Parties; (H) develop and adopt or amend, as applicable, the CHD Registration Protocol the Compound Receipt, Handling and Storage Services Protocols and the Stored Compound Distribution Services Protocols and (I) facilitate on-going
communications between the Parties. 

  

	 	(iii)	Operating Procedures of the Steering Committee; Decision by Steering Committee; Steering Committee Minutes. The Steering Committee shall establish its own
internal operating procedures and meeting schedule (such meetings to be held in person or by video or telephone conference as mutually agreed upon by the representatives comprising such Steering Committee); provided, however, such Steering Committee
shall meet (A) at least once every month and (B) on a face-to-face basis at least once every quarter. Any matter which requires a decision by, or the approval of, the Steering Committee under this Agreement shall require the affirmative
consent of each representative of the Steering Committee. At each meeting of the Steering Committee, one (1) representative shall be appointed to record and, within a period of two (2) weeks after each such meeting, distribute the minutes
of such meeting to the Services Managers for approval (the approval of the content of each such meeting minutes to be evidenced by the initialing of such meeting minutes by each Services Manager). 

 

	 	(b)	Appointment of the Services Managers; Responsibilities of the Services Managers. 

 

	 	(i)	Appointment of the Services Managers. Promptly following the execution of this Agreement, each Party shall appoint (A) a services manager (the
“Biology Services Manager”) to oversee the day-to-day coordination, implementation and performance of the Biology Services and (B) a services manager (the “Medicinal Chemistry Services Manager” and, together
with the Biology Services Manager, the “Services Managers”) to oversee the day-to-day coordination, implementation and performance of the Medicinal Chemistry Services. The Services Managers shall meet (by video or telephone
conference) on at least a bi-weekly basis. Evotec hereby agrees that each Services Manager appointed by Evotec shall be subject to the consent of the Foundation (such consent not to be unreasonably withheld). Upon the reasonable written request of
the Foundation, Evotec shall, in a reasonable period of time following such request, replace any Services Manager designated by Evotec (any such designated replacement to be subject to the consent of the Foundation (such consent not to be
unreasonably withheld)). 

  

 18 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	(ii)	Responsibilities of the Services Managers. The Services Managers shall, among other things, (A) develop and define (but not approve) the description and
scope of each Project (including setting forth the number of Services FTEs to be designated to complete each such Project, the estimated timeframe to complete each such Project and the Foundation Provided Compounds, Foundation Provided Materials,
Foundation Provided Methods and Processes and Foundation Provided Services Information for each such Project); (B) oversee the coordination, implementation and performance of the Services in respect of the Projects; (C) review the status
and progress of the Projects; (D) review and discuss the Services Deliverables, Services Results and such other matters related to this Agreement and the Services as requested by either of the Parties; and (E) facilitate on-going
communications between the Parties. 

  

	 	(c)	Appointment of the Project Managers; Responsibilities of the Project Managers. 

 

	 	(i)	Appointment of the Project Managers. Promptly following the execution of this Agreement and from time to time thereafter as additional Projects are initiated,
each Party shall appoint a project manager (each, a “Project Manager”) to oversee the day-to-day coordination, implementation and performance of the Services in respect of each Project. The Project Managers on each Project shall
meet (by video or telephone conference) on at least a bi-weekly basis. Evotec hereby agrees that each Project Manager appointed by Evotec shall be subject to the consent of the Foundation (such consent not to be unreasonably withheld). Upon the
reasonable written request of the Foundation, Evotec shall, in a reasonable period of time following such request, replace any Project Manager designated by Evotec (any such designated replacement to be subject to the consent of the Foundation (such
consent not to be unreasonably withheld)). 

  

	 	(ii)	Responsibilities of the Project Managers. The Project Managers shall, among other things, with respect to each Project for which they are responsible
(A) oversee the day-to-day coordination, implementation and performance of the Services in respect of each such Project; (B) review the status and progress of each such Project; (C) determine if changes are needed to the scientific
aspects of each such Project and implement any such changes as directed by the Foundation’s Services Manager; (D) determine if changes are needed to the non-scientific aspects of each such Project (including the number of Services FTE
assigned to each such Project as well as costs related to (1) Evotec Provided Reimbursable Materials, (2) Specialized Third Party Licenses and Services and (3) data collection related to the performance of Structural Biology Services
requiring synchrotron data collection required for such Project) and submit any such changes to the Services Managers and/or Steering Committee for consideration and approval as specified under this Agreement; (E) implement any non-scientific
changes to a Project which have been approved by the Services Managers and/or Steering Committee as specified under this Agreement; (F) review and discuss the Services Deliverables and Services Results related to each such Project and such
other matters related to this Agreement and each such Project as requested by either of the Project Managers or Services Managers; and (G) facilitate on-going communications between the Parties. With respect to each Project for which an Evotec
Project Manager is responsible, the Evotec Project Manager shall promptly inform the Foundation’s Project Manager of any matter that materially affects the progress of the performance of the Services in respect of each such Project (including
the ability to complete each such Project within the estimated time frame for the completion of each such Project as well as any other matter related to each such Project as reasonably requested by the Foundation’s Project Manager.

  

	 	(d)	Limited Authority of the Steering Committee, Services Managers and Project Managers. For the avoidance of any doubt, the Parties hereby acknowledge and agree
that neither the Steering Committees, the Services Managers nor the Project Managers shall have the power or authority to 

  

 19 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	
(i) increase the number of Services FTEs under this Agreement; (ii) waive any right or obligation of a Party under this Agreement; or (iii) amend this Agreement. The Parties hereby
further acknowledge and agree that each of the matters described in (i), (ii) and (iii) above may only be effectuated by the written agreement of the Parties signed by an authorized representative of each of the Parties (with respect to
the Foundation, such authorized representative to be an individual other than the members of the Steering Committee designated by the Foundation, the Foundation’s Services Managers and the Foundation’s Project Managers).

  

	 	(e)	Project Reports. Evotec shall, with respect to each Project, deliver (i) interim project reports (each, an “Interim Project Report”)
(A) to the Foundation’s Project Manager responsible for such Project on a bi-weekly basis (each such bi-weekly Interim Project Report to be delivered at least one (1) business day prior to the Project Managers’ regularly
scheduled bi-weekly meeting) and (B) to the Steering Committee on a monthly basis (each such monthly Interim Project Report to be delivered at least five (5) business days prior to the Steering Committee’s regularly scheduled meeting
for such month) and (ii) final project reports (the “Final Project Reports” and, together with the Interim Project Reports, the “Project Reports”) to the Steering Committee promptly following the completion or
cancellation of each Project. The Project Report for each Project shall provide (1) a summary of the status and progress of such Project (including the status of the completion time frame of such Project as compared to the estimated time frame
specified for such Project), (2) material developments and issues in respect of each Project, (3) a list setting forth the name and title of each person provided by the Company to constitute all or part of the Services FTEs (including with
respect to each such person all of the following information: a) whether such person constitutes a Permanent Biology Services FTE, a Permanent Compound Management Services FTE, a Permanent Medicinal Chemistry Services FTE or a Foundation Designated
Services FTE, b) if such person constitutes a Foundation Designated Services, specify whether such person performed Biology Services, Compound Management Services or Medicinal Chemistry Services and c) the percent effort such person devoted to the
conduct of the Projects (broken down on a Project-by-Project basis) during the period covered by the Project Report and (4) such other matters related to each Project as reasonably requested by the Foundation’s Project Manager.

  

	 	(f)	Recordkeeping. Evotec shall keep complete and accurate records of all Services performed by it under this Agreement and of all Services Results and Services
Deliverables. Such records (including all applicable laboratory notebooks containing data, information or notations relating to the provision of the Services) shall be available at all reasonable times during normal business hours for inspection,
examination or copying by or on behalf of the Foundation at the Foundation’s expense. Evotec hereby agrees to retain all such records, including all raw data, for a period of not less than five (5) years from the date of termination of
this Agreement. During such five-year period, Evotec shall, at the Foundation’s request and expense, ship all or part of such records to the Foundation or to such third party as the Foundation shall direct in writing. Upon the expiration of
such five-year period, Evotec shall appropriately discard or destroy all records that have not been shipped at the direction of the Foundation. 

Payments 
  

	8.	General Payment Obligation; Costs of the Services; Reimbursable Costs; Calculation of the Monthly Services Payment; Invoicing; Bring-Down of Representations; Payment
Remittance; Late Payments. 

  

	 	(a)	General Payment Obligation. In full consideration of the performance by Evotec of the Services and its obligations under this Agreement, the Foundation shall
make payments to Evotec for the Services 

  

 20 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	
performed by Evotec as provided in, and subject to the terms and conditions of, this Agreement. The amount of each payment to be made by the Foundation for the Services provided by Evotec under
this Agreement shall be calculated in accordance with the terms of this Section 8. 

  

	 	(b)	Costs of the Services. 

  

	 	(i)	Applicable Services FTE Rate. For purposes of this Agreement, “Applicable Services FTE Rate” means, for all Services FTEs (on a monthly basis),
(A) if the number of Services FTEs is less than or equal to seven (7), an amount equal to US$[***]; (B) if the number of Services FTEs is greater than seven (7) but less than or equal to ten (10), an amount equal to US$[***]; and
(C) if the number of Services FTEs is greater than ten (10), an amount equal to US$[***]. For all purposes of this Agreement, the Applicable Services FTE Rate for a calendar month shall be determined based upon the number of Services FTEs as of
the first day of that calendar month. 

  

	 	(ii)	Compound Purification Services. With respect to the Compound Purification Services performed by Evotec, the cost of such Compound Purification Services shall
determined and calculated as follows: 

  

	 	(A)	with respect to Compound Purification Services in respect of chemically similar Compounds in quantities of less than one hundred (100) milligrams per Compound
which can be purified (1) utilizing substantially the same methods and (2) in batches of twenty (20) or more Compounds, an amount equal to US$[***] per Compound purified by Evotec; 

 

	 	(B)	with respect to Compound Purification Services in respect of Compounds (1) in quantities of greater than one hundred (100) milligrams per Compound or
(2) which cannot be purified (x) utilizing substantially the same methods and (y) in batches of twenty (20) or more Compounds, an amount equal to US$[***] for each one hundred (100) milligrams (or lesser amount thereof) of
Compound purified by Evotec up to a total of one gram of Compound purified (e.g., the purification of seventy-five (75) milligrams, two hundred and fifty (250) milligrams and four hundred (400) milligrams of a Compound would cost
US$[***], US$[***] and US$[***], respectively); and 

  

	 	(C)	with respect to Compound Purification Services in respect of a Compound in an amount greater than one gram or any such case as cannot be covered by
Section 8(b)(ii)(A) or Section 8(b)(ii)(B) of this Agreement, such Compound Purification Services shall be carried out by a Medicinal Chemistry Services FTE and charged at the Applicable Services FTE Rate.

  

	 	(c)	Reimbursable Costs. 

  

	 	(i)	Compounds Procured by Evotec During the Performance of the Compound Procurement Services. Subject to Section 3(b) of this Agreement, the Foundation
shall reimburse Evotec for the costs incurred by Evotec to procure any Compound procured by Evotec during the course of the performance by Evotec of the Compound Procurement Services under this Agreement (collectively, the “Compound
Procurement Costs”). For the avoidance of any doubt, the reimbursement of the Compound Procurement Costs, shall be in addition to the cost of the Services FTEs performing such Compound Procurement Services which will be invoiced in addition
to such Chemical Procurement Costs on a monthly basis as set forth in Section 8(d)(i) of this Agreement. 

  

 21 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	(ii)	Evotec Provided Reimbursable Materials. Subject to Section 5(a) of this Agreement, the Foundation shall reimburse Evotec for the costs incurred by
Evotec to procure any Evotec Provided Reimbursable Materials (collectively, the “Evotec Provided Reimbursable Materials Costs”). 

  

	 	(iii)	Specialized Third Party Licenses and Services. Subject to Section 6(a) of this Agreement, the Foundation shall reimburse Evotec for the costs
incurred by Evotec in connection with the Specialized Third Party Licenses and Services (collectively, the “Specialized Third Party Licenses and Services Costs”). 

 

	 	(iv)	Synchrotron Data Collection. Subject to Section 6(b) of this Agreement this Agreement, the Foundation shall reimburse Evotec for all costs incurred
by Evotec for synchrotron data collection related to the performance of Structural Biology Services requiring synchrotron data collection (including any travel, lodging and meal expenses incurred by Evotec’s personnel in the performance of such
synchrotron data collection (collectively, the “Synchrotron Data Collection Costs”). Evotec hereby agrees that (A) unless otherwise agreed in writing by the Foundation, all travel and lodging for employees of Evotec performing
specific Structural Biology Services shall be arranged through the Foundation and (B) all travel, lodging and meal expenses expenditures shall be in accordance with the Foundation’s travel, lodging and meal expense policies and procedures.

  

	 	(v)	Shipping and Insurance. The Foundation shall reimburse Evotec for (A) all costs of carriage, customs duties and insurance incurred by Evotec in connection
with the delivery of the Services Deliverables to the Foundation (or such third party specified by the Foundation) and (B) all costs and expenses incurred by Evotec in connection with the delivery of such Services Deliverables (collectively,
the “Shipping and Insurance Costs”). 

  

	 	(d)	Calculation of the Monthly Services Payment. 

  

	 	(i)	General. Promptly following the end of each calendar month, Evotec shall calculate the payment (each, a “Monthly Services Payment”) to be made
by the Foundation in respect of (A) the Services FTEs performing Services during such month (including Compound Procurement Services and Compound Purification Services performed on a Services FTE basis); (B) the Compound Procurement Costs
incurred by Evotec during such month to be reimbursed by the Foundation; (C) the Compound Purification Services performed during such month (on a non-Services FTE basis); (D) the Evotec Provided Reimbursable Materials Costs incurred by
Evotec during such month to be reimbursed by the Foundation; (E) the Specialized Third Party Licenses and Services Costs incurred by Evotec during such month to be reimbursed by the Foundation; (F) the Synchrotron Data Collection Costs
incurred by Evotec during such month to be reimbursed by the Foundation; and (G) the Shipping and Insurance Costs incurred by Evotec during such month to be reimbursed by the Foundation. 

 

	 	(ii)	Specific Calculation of the Monthly Services Payment. The Monthly Services Payment in respect of each calendar month shall be calculated in accordance with the
terms of this Agreement and shall be an amount equal the sum of (A) the aggregate sum of the result of the following calculation as determined for each Services FTE during such month: the product of (1) the Applicable FTE Rate for such
month multiplied by (2) a fraction, the numerator of which is the number of days during such month that such Services FTE was assigned to perform Services (including Compound Purification Services performed on a Services FTE basis) and
the denominator of which is the number of days in such month multiplied by (3) 1.0 (or if such Services FTE represents a fraction of one (1) FTE (e.g. 0.75, 0.5 or 0.25 of an FTE) such 

 

 22 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	
fractional unit thereof plus (B) the aggregate amount of the Compound Procurement Costs incurred by Evotec during such month; (C) the aggregate cost of the Compound Purification
Services performed during such month (on a non-Services FTE basis); (D) the aggregate amount of the Evotec Provided Reimbursable Materials Costs incurred by Evotec during such month; (E) the aggregate amount of the Specialized Third Party
Licenses and Services Costs incurred by Evotec during such month; (F) the aggregate amount of the Synchrotron Data Collection Costs incurred by Evotec during such month; and (G) the aggregate amount of the Shipping and Insurance Costs
incurred by Evotec during such month. 

  

	 	(e)	Invoicing; Bring-Down of Representations. 

  

	 	(i)	Invoicing. Promptly following the calculation of the amount of each Monthly Services Payment, Evotec shall deliver to the Foundation, in accordance with
Section 16 of this Agreement, an invoice in respect of the costs constituting such Monthly Services Payment. Each invoice delivered by Evotec under this Agreement shall (A) reference the “RecID” number set forth in the
footer of this Agreement and (B) be itemized and contain detailed information in respect of the costs being billed under such invoice (including all relevant receipts for costs being reimbursed). All payments made by the Foundation under this
Agreement shall be paid by check in US Dollars and remitted to Evotec at the address set forth in Section 16 of this Agreement. 

  

	 	(ii)	Bring-Down of Representations. Evotec hereby agrees that each invoice delivered by Evotec to the Foundation in respect of any Monthly Services Payment shall be
deemed a certification by Evotec that as of the date of such invoice (A) each of the representations and warranties of Evotec set forth in this Agreement are true and correct and (B) there is no breach by Evotec of any covenant of Evotec
set forth in this Agreement. 

  

	 	(f)	Payment Remittance; Late Payments. 

  

	 	(i)	Payment Remittance. Subject to the terms and conditions of this Agreement, each Monthly Services Payment to be made by the Foundation under this Agreement shall
be due and payable by the Foundation within thirty (30) days of the date of the receipt by the Foundation of the invoice issued by Evotec in accordance with Section 8(e)(i) of this Agreement in respect of such Monthly Services
Payment. 

  

	 	(ii)	Late Payments. If the Foundation fails to pay any amount due under this Agreement in full by the due date for the payment of such amount, then Evotec may,
without prejudice to any other right or remedy available to it, charge interest on such overdue amount on a daily basis at a rate equivalent to 8% per annum. 

 

	 	(g)	Withholding Taxes. All amounts payable by the Foundation under this Agreement shall be paid in full without any deductions (including, but not limited to,
deductions in respect of items such as income, corporation or other taxes, charges and/or duties) except insofar as the Foundation is required by law to deduct withholding tax from sums payable to Evotec. If the Foundation is required by law to
deduct any withholding taxes, charges or other duties, then the Foundation and Evotec shall cooperate in all respects and take all reasonable steps necessary, at the cost and expense of Evotec, to (i) lawfully avoid the making of any such
deduction or (ii) to enable Evotec to obtain a tax credit in respect of the amount withheld. 

  

 23 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

 Results 

 

	9.	Ownership of Services Results; Notification and Delivery of Services Results; Ownership of Services Deliverables; Transfer of Title, Delivery and Transport of
Services Deliverables; Transfers of the Services Deliverables. 

  

	 	(a)	Ownership of Services Results. As between the Foundation and Evotec, the Foundation shall own all Services Results. Evotec shall have no ownership or other
interest in any Services Results. Evotec hereby assigns, and agrees to assign, to the Foundation any and all right, title and interest of Evotec in and to the Services Results. Upon the written request of the Foundation, Evotec shall execute such
documents and do all other acts and things as may be reasonably deemed necessary by the Foundation to effectuate and assure that all right, title and interest of Evotec in and to the Services Results vest in the Foundation (or its designee). The
Foundation shall reimburse Evotec for all reasonable out-of-pocket costs and expenses actually incurred by Evotec to execute and deliver to the Foundation any such document(s) referred to immediately above. 

 

	 	(b)	Notification and Delivery of Services Results; Withdrawal of Services Results. 

 

	 	(i)	Notification and Delivery of Services Results. Evotec shall inform the Foundation of, and deliver, all Services Results to the Foundation within a reasonable
period of time following the conception, discovery, invention or production, as the case may be, of each such Services Result through the monthly Steering Committee meetings and Project Reports. 

 

	 	(ii)	Withdrawal of Services Results. If at any time after informing the Foundation of Services Results pursuant to Section 9(b)(i) of this Agreement
Evotec determines that there is a reasonable scientific basis to conclude that such Services Results are not scientifically valid or accurate, Evotec shall promptly so notify the Foundation. 

 

	 	(c)	Ownership of Services Deliverables; Transfer of Title, Delivery and Transport of Services Deliverables; Transfers of the Services Deliverables.

  

	 	(i)	Ownership of Services Deliverables. As between the Foundation and Evotec, the Foundation shall own all Services Deliverables. Evotec shall have no ownership or
other interest in any Services Deliverables. Evotec hereby assigns, and agrees to assign, to the Foundation any and all right, title and interest of Evotec in and to the Services Deliverables. Upon the written request of the Foundation, Evotec shall
execute such documents and do all other acts and things as may be reasonably deemed necessary by the Foundation to effectuate and assure that all right, title and interest of Evotec in and to the Services Deliverables vest in the Foundation (or its
designee). The Foundation shall reimburse Evotec for all reasonable out-of-pocket costs and expenses actually incurred by Evotec to execute and deliver to the Foundation any such document(s) referred to immediately above. 

 

	 	(ii)	Transfer of Title, Delivery and Transport of Services Deliverables. Title to, and all risk of loss in, each Services Deliverable shall pass to the Foundation
upon the delivery of such Services Deliverable to the delivery point specified by the Foundation (CIF or CIP, as applicable) (Incoterms 2000) in writing to Evotec for such Services Deliverable. All Services Deliverables shall be shipped to the
delivery point specified by the Foundation in writing to Evotec. 

  

	 	(iii)	Transfers of the Services Deliverables to Foundation Collaborators. Evotec hereby acknowledges that the Foundation may transfer or have transferred the Services
Deliverables to one or more of the Foundation’s Collaborators and that such Foundation Collaborators shall be permitted to exercise the license rights granted by Evotec pursuant to Section 10(h)(i) of this Agreement.

  

 24 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

 Intellectual Property 

 

	10.	Ownership of Background Intellectual Property; Ownership of Services Intellectual Property; Ownership of Assay Development Services Intellectual Property; Ownership
of Evotec Medicinal Chemistry Intellectual Property; Disclosure of Inventions; Patent Filings; Inventorship. 

  

	 	(a)	Ownership of Background Intellectual Property. 

  

	 	(i)	Ownership of Evotec Background Intellectual Property. As between the Foundation and Evotec, Evotec shall own all Evotec Background Intellectual Property. Except
as expressly set forth in this Agreement, the Foundation shall have no ownership or other interest in any Evotec Background Intellectual Property. 

  

	 	(ii)	Ownership of Foundation Background Intellectual Property. As between the Foundation and Evotec, the Foundation shall own all Foundation Background Intellectual
Property. Evotec shall have no ownership or other interest in any Foundation Background Intellectual Property. 

  

	 	(b)	Ownership of Services Intellectual Property. As between the Foundation and Evotec, the Foundation shall own all Services Intellectual Property. Evotec shall have
no ownership or other interest in any Services Intellectual Property. Evotec hereby assigns, and agrees to assign, to the Foundation any and all right, title and interest of Evotec in and to the Services Intellectual Property. Upon the written
request of the Foundation, Evotec shall execute such documents and do all other acts and things as may be reasonably deemed necessary by the Foundation to effectuate and assure that all right, title and interest of Evotec in and to the Services
Intellectual Property vest in the Foundation (or its designee). The Foundation shall reimburse Evotec for all reasonable out-of-pocket costs and expenses actually incurred by Evotec to execute and deliver to the Foundation any such document(s)
referred to immediately above. 

  

	 	(c)	Ownership of Assay Development Services Intellectual Property; Infringement or Misappropriation of Assay Development Services Intellectual Property by Third Parties;
Infringement or Misappropriation Claims by Third Parties Related to Assay Development Services Intellectual Property. 

  

	 	(i)	Ownership of Assay Development Services Intellectual Property. Evotec and the Foundation shall own as tenants-in-common in equal undivided shares all Assay
Development Services Intellectual Property. The Assay Development Services Intellectual Property shall vest in the Parties in that manner immediately upon creation. Each Party hereby assigns to the other Party sufficient right, title and interest in
the Assay Development Services Intellectual Property to accomplish such ownership. For the avoidance of any doubt, each of the Foundation and Evotec hereby acknowledge and agree that (A) each of the Foundation and Evotec and their respective
licensees and assignees, including the Foundation Collaborators and Evotec Customers, shall be allowed to use the Assay Development Services Intellectual Property for any purpose including internal research, drug discovery and development and/or fee
for services arrangements (and each of the Foundation and Evotec hereby consents to the licensing or assignment of the other Party of such Party’s interest in the Assay Development Services Intellectual Property) and (B) any such use of
the Assay Development Services Intellectual Property by any of the foregoing shall be without any financial obligation to the other Party. Each of Evotec and the Foundation hereby agrees that it will not sell or otherwise transfer its title to any
Assay Development Services Intellectual Property to any third party unless such third party takes title to such Assay Development Services Intellectual Property (1) subject to the rights of the non-transferring party in such Assay Development
Services Intellectual Property under this Agreement and (2) assumes the obligations of the transferring party with respect to such Assay Development Services Intellectual Property under this Agreement. 

 

 25 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	(ii)	Infringement or Misappropriation of Assay Development Services Intellectual Property by Third Parties. Each of Evotec and the Foundation hereby agrees to
promptly notify each other in writing of any alleged or threatened infringement or misappropriation of any Assay Development Services Intellectual Property of which it becomes aware. In connection with any such alleged or threatened infringement or
misappropriation, each of Evotec and the Foundation hereby agrees to confer and take such action and allocate recoveries in such manner as they may mutually agree. Neither Evotec nor the Foundation shall settle a claim brought against a third party
in respect of such infringement or misappropriation without the consent of the other. 

  

	 	(iii)	Infringement or Misappropriation Claims by Third Parties Related to Assay Development Services Intellectual Property. Each of Evotec and the Foundation hereby
agrees to promptly notify the other Party in writing if any third party alleges that any Assay Development Services Intellectual Property infringes or misappropriate such third party’s Intellectual Property rights. In connection with any such
alleged infringement or misappropriation, each of Evotec and the Foundation hereby agrees to confer and take such action in such manner as they may mutually agree. Neither Party shall settle a claim brought by a third party in respect of such
infringement or misappropriation without the consent of the other Party. 

  

	 	(d)	Ownership of Evotec Medicinal Chemistry Intellectual Property. As between the Foundation and Evotec, Evotec shall own all Evotec Medicinal Chemistry Intellectual
Property. Except as expressly set forth in this Agreement, the Foundation shall have no ownership or other interest in any Evotec Medicinal Chemistry Intellectual Property. 

 

	 	(e)	Disclosure of Inventions; Patent Filings. If either Party believes any Services Intellectual Property, Assay Development Services Intellectual Property or Evotec
Medicinal Chemistry Intellectual Property has been conceived, discovered, invented or made in the course of the performance of the Services, such Party will promptly give notice of such Intellectual Property to the other Party. As between the
Parties, (i) the Foundation shall have the exclusive right to file patent applications in respect of any Services Intellectual Property and (ii) Evotec shall have the exclusive right to file patent applications in respect of any Assay
Development Services Intellectual Property or Evotec Medicinal Chemistry Intellectual Property. Each Party shall, upon the request and at the expense of the other Party, use its reasonable efforts to assist such other Party with any patent
application relating to any such Intellectual Property. 

  

	 	(f)	Inventorship. The Parties hereby agree that the identity of the inventor of all Intellectual Property conceived, discovered, invented or made in the course of
the performance of the Services (including all Services Intellectual Property and Assay Development Services Intellectual Property) shall be determined in accordance with United States Patent law (or, if the jurisdiction in which patent or other
protection is being sought does not permit the application of United States Patent law to identify the inventor, then in accordance with the applicable law in that jurisdiction). 

 

	 	(g)	Right to use Intellectual Property and Results in the Public Domain. Nothing contained in this Agreement shall restrict, hinder or prohibit the right of either
Party to use any Intellectual Property or any know-how, methods, results, data or information (including any Assays, Structures, Targets, Evotec Library Compounds, Foundation Provided Materials or Services Compounds) of the other Party which is
freely available and in the public domain; provided, that, such Intellectual Property or any know-how, methods, results, data or information (including any Assays, Evotec Library Compounds, Foundation Provided Materials or Services Compounds) did
not become available in the public domain due to a breach of a Party’s confidentiality and non-use obligations set forth in Section 11 of this Agreement. 

 

 26 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	(h)	License to Background Intellectual Property. 

  

	 	(i)	 License to Evotec Background Intellectual Property for the Foundation and Foundation Collaborators. Evotec hereby grants to the Foundation and
each Foundation Collaborator a non-exclusive, paid-up, irrevocable, perpetual license throughout the world to use Evotec Background Intellectual Property, including a license under any related Intellectual Property rights (including any patent,
patent application, divisional, continuation, continuation-in-part, substitute, renewal, reexamination, extension of reissue in respect of such patent), to the extent necessary to enable use of the Services Results (including any Services
Deliverable), Services Intellectual Property and Assay Development Services Intellectual Property for HD Research and Development by the Foundation and the Foundation Collaborators; provided, however, to the extent any such Evotec Background
Intellectual Property is licensed by Evotec from a third party, the Parties hereby acknowledge and agree that the license rights granted by Evotec pursuant to this Section 10(h)(i) shall be expressly limited by the terms (including
restrictions thereon) and scope of the license rights granted to Evotec by such third party. Evotec hereby represents and warrants that Evotec is prohibited contractually from granting any licenses to the Evotec Library Compounds, the
EVOscreen® Technology, the FCS+plus Technology, the Miniaturization Technology and the
OperaTM Technology. The Foundation, subject to the representation and warranty in the preceding sentence, hereby
acknowledges and agrees Evotec is contractually prohibited from granting to the Foundation and the Foundation Collaborators under this Section 10(h)(i) a license to the Evotec Library Compounds, the
EVOscreen® Technology, the FCS+plus Technology, the Miniaturization Technology or the
OperaTM Technology. For the avoidance of doubt, the use of any Evotec Background Intellectual Property pursuant
to this Section 10(h)(i) shall be solely for the use of the Services Results (including any Services Deliverable), Services Intellectual Property and Assay Development Services Intellectual Property for HD Research and Development and
for no other purpose. 

  

	 	(ii)	License to Foundation Background Intellectual Property for Evotec and the Evotec Customers. The Foundation hereby grants to Evotec and each Evotec Customer a
non-exclusive, paid-up, irrevocable, perpetual license throughout the world to use Foundation Background Intellectual Property, including a license under any related Intellectual Property rights (including any patent, patent application, divisional,
continuation, continuation-in-part, substitute, renewal, reexamination, extension of reissue in respect of such patent), to the extent necessary to enable use of the Assay Development Services Intellectual Property for any purpose by Evotec and the
Evotec Customers; provided, however, to the extent any such Foundation Background Intellectual Property is licensed by the Foundation from a third party, the Parties hereby acknowledge and agree that the license rights granted by the Foundation
pursuant to this Section 10(h)(ii) shall be expressly limited by the terms (including restrictions thereon) and scope of the license rights granted to the Foundation by such third party. 

Confidentiality; Trademarks 
  

	11.	Confidentiality and Non-Use; Use by Representatives; Exceptions to Confidentiality and Non-Use; Certain Information Deemed Confidential Information.

  

	 	(a)	Confidentiality and Non-Use; Use by Representatives. 

  

	 	(i)	Confidentiality and Non-Use. Each Party shall treat the Confidential Information of the other Party in the same manner as such Party would treat its own
confidential or proprietary 

  

 27 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	
information. Without limiting the generality of the foregoing, and except to the extent expressly permitted by the terms and conditions of this Agreement, neither Party shall, without the prior
written consent of the other Party, (A) disclose the Confidential Information of the other Party to any third party or (B) use the Confidential Information of the other Party for any purpose. 

 

	 	(ii)	Use by Representatives. Except as expressly permitted by the terms and conditions of this Agreement, each Party hereby agrees to limit disclosure of the other
Party’s Confidential Information to those of its directors, officers, employees, representatives, consultants, Subcontractors and advisors (including legal counsel) who (A) have a need to know such Confidential Information to enable such
Party to perform its obligations, or exercise its rights, under this Agreement and (B) have entered into an agreement which requires such representatives to maintain similar, but no less burdensome, obligations of confidentiality and non-use to
those contained in this Agreement. 

  

	 	(b)	Exceptions to Confidentiality and Non-Use. Either Party may, without the prior written authorization of the other Party, (i) may disclose the Confidential
Information of the other Party to the limited extent it is required to pursuant to any applicable federal, state, local, or international law, or any judicial or government request, requirement or order; provided, that, such Party provides the other
Party with sufficient prior notice, and cooperates with the other Party (at such other Party’s cost and expense), to allow the other Party to contest such request, requirement or order and (ii) disclose (A) the existence of this
Agreement; (B) a general summary of the Services being provided under this Agreement; (C) the aggregate dollar amount of fees to be paid by the Foundation under this Agreement; and (D) any specific terms of this Agreement that are a
matter of public record except by breach of this Agreement. 

  

	 	(c)	Certain Information Deemed Confidential Information; Certain Information Specifically Excepted from Being Deemed Confidential Information.

  

	 	(i)	Certain Information Deemed Confidential Information. The Parties hereby agree that all Evotec Background Intellectual Property and Evotec Medicinal Chemistry
Intellectual Property shall be deemed Confidential Information of Evotec and treated as Confidential Information by the Foundation in accordance with the terms of this Section 11. Evotec hereby agrees that all Foundation Provided
Compound Information, Foundation Provided Methods and Processes, Foundation Provided Material Information, Foundation Provided Services Information, Foundation Background Intellectual Property, Services Intellectual Property, Services Results and
Project Reports shall be deemed Confidential Information of the Foundation and treated as Confidential Information by Evotec in accordance with the terms of this Section 11. 

 

	 	(ii)	Certain Information Specifically Excepted from Being Deemed Confidential Information. For the avoidance of any doubt, the Parties hereby acknowledge and agree
that any information deemed to be Confidential Information pursuant to Section 11(c)(i) of this Agreement shall not constitute Confidential Information under this Agreement if in accordance with Section 1(q) of this Agreement
such information constitutes information which is specifically excepted from being Confidential Information. 

  

	12.	Use of Trademarks. No Party shall use the name, trademarks, logos, physical likeness or other symbol of the other Party (or their employees) for any marketing,
advertising, public relations or other purposes without the prior written authorization of the other Party, except that either Party may make reference to the Foundation’s sponsorship of the Projects, provided that, in any such reference, the
relationship of the Parties shall be accurately and appropriately described. Notwithstanding the foregoing, either Party may make a press announcement; provided, that, the timing and content of any such press announcement shall be agreed upon in
advance by the other Party (which consent shall not be unreasonably withheld or delayed). 

  

 28 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

 Covenants 

 

	13.	Representations and Covenants. 

  

	 	(a)	Representations and Covenants of Evotec. Evotec hereby agrees to each of the following: 

 

	 	(i)	Compliance with Law. The Services will be conducted in compliance with all applicable federal, state, local, international, health authority and institutional
laws, rules, regulations, orders and guidelines. 

  

	 	(ii)	Audit. At reasonably convenient times and dates, the Foundation and its representatives shall have the right to audit Evotec’s compliance with this
Agreement; provided, that, such representatives are bound by confidentiality obligations equivalent to those of this Agreement. 

  

	 	(iii)	Services Team. The Services shall only be conducted by individuals who have agreed to assign any ownership or other rights they may acquire in any Services
Intellectual Property or Assay Development Services Intellectual Property conceived, discovered, invented or made in the course of the performance of the Services under this Agreement to Evotec so that Evotec may perform its obligations under this
Agreement. Evotec shall directly assign or shall cause any such individual to assign any such Services Intellectual Property or Assay Development Services Intellectual Property conceived, discovered, invented or made in the course of the performance
of the Services under this Agreement to the Foundation. 

  

	 	(iv)	Licenses and Approvals. Evotec has obtained all, and will obtain all, future, licenses, permits, consents and other approvals necessary for Evotec (A) to
enter into this Agreement and (B) to perform its obligations, and convey the rights granted by it, under this Agreement, including (1) the right to deliver the physical samples of the Services Compounds to the Foundation and (2) the
right to disclose the Compound Data to the Foundation. 

  

	 	(v)	Conflicting Obligations. Evotec has not granted any right or entered into any agreement or understanding that conflicts with Evotec’s obligations or the
Foundation’s rights under this Agreement. Evotec will not grant any right and will not enter into any agreement or understanding that conflicts with Evotec’s obligations or the Foundation’s rights under this Agreement.

  

	 	(vi)	Intellectual Property. Except for Intellectual Property in respect of (A) the composition of matter of a Services Compound or a Structure, (B) any use
of a Services Compound, Evotec Library Compound or a Structure by the Foundation, (C) any use of a Target by Evotec pursuant to this Agreement, (D) any use of Foundation Provided Methods and Processes by Evotec pursuant to this Agreement
or (E) any use of any Foundation Provided Compound, Foundation Provided Material, Foundation Provided Material Information or Foundation Provided Services Information by Evotec pursuant to this Agreement, to the knowledge of Evotec (after due
inquiry and investigation), Evotec owns or has the right to use pursuant to a valid and enforceable, written license, sublicense, agreement, or other permission, all Intellectual Property necessary to perform the Services and the other obligations
of Evotec under this Agreement, including the right to grant the licenses in Section 10(h) of this Agreement. Evotec will use commercially reasonable efforts to ensure that Evotec’s performance of the Services will not infringe upon
or misappropriate the Intellectual Property rights of any third party (other than Intellectual Property rights in respect of (1) the composition of matter of a Services Compound or a Structure, (2) any use of a Services Compound, Evotec
Library Compound or a Structure by the Foundation, (3) any use of a Target by Evotec pursuant to this Agreement, (4) any use of any Foundation Provided 

 

 29 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	
Methods and Processes by Evotec pursuant to this Agreement or (5) any use of any Foundation Provided Compound, Foundation Provided Material, Foundation Provided Material Information or
Foundation Provided Services Information by Evotec pursuant to this Agreement). Without the prior written consent of the Foundation, Evotec shall not knowingly (after due inquiry and investigation) perform the Services utilizing any Intellectual
Property rights of any third party (other than Intellectual Property rights in respect of any Target, Foundation Provided Materials, Foundation Provided Material Information, Foundation Provided Methods and Processes or Foundation Provided Services
Information) if such utilization could adversely affect or limit the Foundation’s or the Foundation Collaborators’ use of the Services Deliverables, Services Intellectual Property and Services Results, for HD Research and Development.

  

	 	(vii)	Safety Hazards. If Evotec becomes aware of any safety hazard that relates to any of the Assays, Services Compounds, Foundation Provided Compounds or any
Foundation Provided Materials, Evotec shall promptly notify the Foundation of such safety hazard by providing all information in its possession or control concerning such safety hazard to the Foundation. 

 

	 	(viii)	Further Assurances. Evotec shall execute such further documents, instruments, licenses and assurances and take such further actions as the Foundation may
reasonably request from time to time to better enable the Foundation to exercise its rights under this Agreement. 

  

	 	(b)	Representations and Covenants of the Foundation. The Foundation hereby agrees to each of the following: 

 

	 	(i)	Approvals. The Foundation has obtained all, and will obtain all, future, licenses, permits, consents and other approvals necessary for the Foundation to
(A) enter into this Agreement and (B) to perform its obligations, and convey the rights granted by it, under this Agreement. 

  

	 	(ii)	Conflicting Obligations. The Foundation has not granted any right or entered into any agreement or understanding that conflicts with the Foundation’s
obligations or the Foundation’s rights under this Agreement. The Foundation will not grant any right and will not enter into any agreement or understanding that conflicts with the Foundation’s obligations or Evotec’s rights under this
Agreement. 

  

	 	(iii)	Intellectual Property. To the knowledge of the Foundation (after due inquiry and investigation), the use by Evotec of the Foundation Provided Compounds,
Foundation Provided Compound Information, Foundation Provided Materials, Foundation Provided Material Information, Targets, Foundation Provided Methods and Processes and Foundation Provided Services Information in the performance of the Services
pursuant to this Agreement will not infringe upon or misappropriate the Intellectual Property rights of any third party. 

  

	 	(iv)	Safety Hazards. If the Foundation becomes aware of any safety hazard that relates to any of the Assays, Services Compounds, Foundation Provided Compound or any
Foundation Provided Material, the Foundation shall promptly notify Evotec of such safety hazard by providing all information in its possession or control concerning such safety hazard to Evotec. 

 

	 	(v)	Further Assurances. The Foundation shall execute such further documents, instruments, licenses and assurances and take such further actions as Evotec may
reasonably request from time to time to better enable Evotec to exercise its rights under this Agreement. 

  

 30 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

 Term; Termination; Effect of Termination 

 

	14.	Term; Termination of Certain Provisions; Effect of Termination of Certain Provisions. 

 

	 	(a)	Term. The term (the “Term”) of this Agreement shall commence on the Effective Date and shall continue for a period of three (3) years
unless earlier terminated in accordance with the terms hereof or by the mutual written agreement of the Parties. Unless either Party provides written notice to the other Party at least ninety (90) days prior to expiration of the Term or any one
(1) year extension period thereof, the Term (or extension thereof) will automatically extend for a period of one (1) year. 

  

	 	(b)	Termination of Certain Provisions by the Foundation. The Foundation may, by giving notice to Evotec, elect to terminate each of the sections specified in
Section 14(d)(i) of this Agreement and discontinue the Project upon the occurrence and continuation of any of the following events: 

  

	 	(i)	Termination with Advance Notice. The Foundation may, by giving ninety (90) days prior notice to Evotec, elect to terminate each of the sections specified in
Section 14(d)(i) of this Agreement. 

  

	 	(ii)	Breach of this Agreement. If Evotec (A) breaches any material representation, warranty or covenant given by it under this Agreement or (B) defaults in
the performance of any of its material obligations under this Agreement and such breach or default is not remedied within thirty (30) days of the receipt by Evotec of notice of such breach or default from the Foundation.

  

	 	(iii)	Bankruptcy Event. Evotec becomes subject to a Bankruptcy Event. 

  

	 	(c)	Termination of Certain Provisions by Evotec. Evotec may, by giving notice to the Foundation, elect to terminate each of the provisions specified in
Section 14(d)(i) of this Agreement and discontinue the Project upon the occurrence and continuation of any of the following events: 

  

	 	(i)	Breach of this Agreement. If the Foundation (A) breaches any material representation, warranty or covenant given by it under this Agreement or
(B) defaults in the performance of any of its material obligations under this Agreement and such breach or default is not remedied within thirty (30) days of the receipt by the Foundation of notice of such breach or default from Evotec.

  

	 	(ii)	Bankruptcy Event. The Foundation becomes subject to a Bankruptcy Event. 

 

	 	(d)	Effect of Termination of Certain Provisions. 

  

	 	(i)	Termination of Specified Provisions; Survival of Remaining Provisions. Immediately upon an election by the Foundation pursuant to Section 14(b) of
this Agreement or by Evotec pursuant to Section 14(c) of this Agreement, each of Section 2, Section3, Section 4(a)(i), Section 5(a), Section 6, Section 7(a),
Section 7(b), Section 7(c), Section 8 and Section 28 shall immediately terminate and have no further force or effect; provided, however, that, within thirty (30) days of such termination, Evotec
shall deliver a Final Project Report in respect of each Project then in process to the Foundation covering the period through the date of such termination. The Parties hereby acknowledge and agree that in the event of the termination of the
provisions specified in this Section 14(d)(i), all other sections and provisions of this Agreement shall survive indefinitely and remain in full force and effect. 

 

	 	(ii)	Effect of Termination. The Parties hereby acknowledge and agree that the termination of the provisions specified in Section 14(d)(i) of this
Agreement shall not (A) relieve any Party then in breach of this Agreement for any liabilities to the other Party in respect of any breach under this Agreement, (B) relieve either Party from any of the obligations such Party may have to
the extent such obligations accrued prior to the date if such termination or (C) relieve either Party from any of the obligations such Party may have under any of the sections or provisions of this Agreement 

 

 31 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	
that expressly survive any termination of this Agreement. Except in the event of a termination of this Agreement pursuant to Section 14(c)(i) of this Agreement, Evotec shall, in
accordance with, as applicable, Section 4(a)(iv) and Section 5(c) of this Agreement, deliver to the Foundation (1) all unused Foundation Provided Materials (including all Stored Compounds and any Compound Data and
Compound Specifications in respect thereof), (2) all unused Evotec Provided Reimburseable Materials, (3) all Services Deliverables, (4) all Services Results (including all Services Compounds and any Compound Data and Compound
Specifications in respect thereof), and (5) any portion of any Services Results and Services Deliverables produced by Evotec but not yet delivered to the Foundation through the date of the termination of this Agreement; provided, however, if
the Foundation contests the right of Evotec to terminate this Agreement pursuant to Section 14(c)(i) of this Agreement, all of the items described in (1) through (5) above shall be placed in escrow by Evotec until the issue is
resolved in accordance with Section 19 of this Agreement. The Foundation hereby acknowledges and agrees that in the event of the termination of the provisions specified in Section 14(d)(i) of this Agreement, the Foundation
shall be responsible for a pro rata portion of the Monthly Services Payment (as calculated in accordance with Section 8 of this Agreement) through the effective date of termination of this Agreement. 

Miscellaneous 
  

	15.	Independent Contractor. Evotec is acting as an independent contractor and not an agent, joint venturer or partner of the Foundation. Nothing in this Agreement
shall create, evidence or imply any agency, partnership or joint venture between the Parties. Neither Party shall act or describe itself as the agent of the other Party nor shall it represent that it has any authority to make commitments on the
other Party’s behalf. 

  

	16.	Notices. Any notice required or permitted to be given by this Agreement shall be in writing and shall be delivered by personal delivery, facsimile (provided the
sender has evidence of successful transmission) or next-day courier service. Any notice so delivered shall be deemed to be given, delivered and received, if delivered by personal delivery, on the day of delivery and if delivered by facsimile or
courier service, on the day following dispatch. All such notices are to be given or made to the Parties at the following addresses (or to such other address as any Party may designate by a notice given in accordance with the provisions of this
section): 

  

	    	If to the Foundation to: 

  

	    	CHDI Foundation, Inc. 

	    	c/o CHDI Management, Inc. 

	    	350 Seventh Avenue, Suite 601 

	    	New York, NY 10001 

	    	Attention: Ruth Basu 

	    	Fax: 212-239-2101 

  

	    	If to Evotec to: 

  

	    	Evotec (UK) Ltd. 

	    	114 Milton Park 

	    	Abingdon 

	    	Oxon 

	    	OX14 4SA, UK 

	    	Attention: Mark Ashton, Ph.D. 

	    	Executive Vice President, Business Development 

	    	Fax: 011-44-1235-838931 

  

 32 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	    	With a copy to: 

  

	    	Evotec AG 

	    	Schnackenburgallee 114 

  

	    	22525 Hamburg 

	    	Germany 

	    	Attention: Dr. Thomas Hesterkamp 

	    	Fax: +49 40 560 81 222 

  

	17.	Warranty; No Guarantee of Results. 

  

	 	(a)	Limited Warranty; Limitation of Implied Warranties; No Warranty. 

  

	 	(i)	Limited Warranty; Limitation of Implied Warranties. Evotec hereby warrants that (A) the Services will be conducted using generally accepted industry
standards and practices; (B) with respect to each Project, the Services conducted by Evotec under this Agreement shall conform to the standards and specifications (1) as set forth in this Agreement, (2) as provided by this Agreement,
that are directed or specified by the Foundation or (3) as provided by this Agreement, that are otherwise agreed between the Parties as set forth in this Agreement; and (C) with respect to each Services Deliverable, such Services
Deliverable has been made, developed or synthesized to meet the specifications for such Services Deliverable (1) as set forth in this Agreement, (2) as provided by this Agreement, that are directed or specified by the Foundation or
(3) as provided by this Agreement, that are otherwise agreed between the Parties as set forth in this Agreement. All warranties implied by law (whether by statute, common law, trade usage, custom or otherwise) are hereby excluded to the maximum
extent permitted by law. 

  

	 	(ii)	No Warranty. Except as expressly set forth in Section 17(a)(i) of this Agreement, Evotec makes no warranties that the Evotec Library Compounds or the
Services Compounds (A) are fit for any purpose; (B) are safe for use in connection with humans, animals or plants; (C) are non-toxic; (D) are non-hazardous; (E) are new or have never been published; or (F) do not
infringe the Intellectual Property rights of any third party nor that the production or use of the Evotec Library Compounds or Services Compounds by the Foundation (or any of its licensees or transferees) will not infringe the Intellectual Property
rights of any third party (other than Evotec). 

  

	 	(b)	No Guarantee of Results. The Parties hereby acknowledge that, as with all research and development activities, it is not possible to guarantee that the
performance of the Services will be successful within a specified time frame or at all. In particular, the Parties further acknowledge that it is not possible for Evotec to guarantee that the performance of (i) the Structural Biology Services
will generate any Structures; (ii) the Assay Development Services will result in the development of a useful Assay; or (iii) the Profiling Services and Screening Services will generate any Hits. So long as Evotec complies with the
obligations of Evotec set forth in Section 17(a) of this Agreement, the Foundation hereby acknowledges and agrees that Evotec shall not be liable for the failure of the performance of the Services to generate any useful results.

  

	18.	Indemnity; Limitation on Damages. 

  

	 	(a)	Indemnification by the Foundation. The Foundation shall defend and indemnify Evotec, including, as applicable, its directors, officers, employees and agents,
against any and all losses, costs and damages (including reasonable legal fees) suffered by Evotec (and/or such other related persons) in connection with any third party claim to the extent resulting from (i) the Foundation’s negligence or
willful misconduct; (ii) the Foundation’s breach of this Agreement; (iii) the Foundation’s (or any of its 

  

 33 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	
licensee’s (including Foundation Collaborators) or transferee’s) use of the Services Deliverables, Services Results, Services Intellectual Property, Assay Development Services
Intellectual Property or Evotec Background Intellectual Property (but only to the extent such claim does not result from, or arise out of, an action for which Evotec is obligated to indemnify the Foundation pursuant to Section 18(b) of
this Agreement); or (iv) Evotec’s use or alleged use of any Foundation Background Intellectual Property, Foundation Provided Compounds, Foundation Provided Compound Information, Foundation Provided Materials, Foundation Provided Material
Information, Target(s), Foundation Provided Methods and Processes and Foundation Provided Services Information provided by the Foundation to Evotec for the purpose performing the Services (but only to the extent such claim does not result from, or
arise out of, an action for which Evotec is obligated to indemnify the Foundation pursuant to Section 18(b) of this Agreement). For clarity, the Parties hereby agree that the parenthetical clause in the immediately preceding sentence is
not intended to obviate or otherwise limit the possibility that both Evotec and the Foundation may be determined to be joint tort-feasors and, therefore, share liability. 

 

	 	(b)	Indemnification by Evotec. Evotec shall defend and indemnify the Foundation, including, as applicable, its members, directors, officers, employees and agents,
against any and all losses, costs and damages (including reasonable legal fees) suffered by the Foundation (and/or such other related persons) in connection with any third party claim to the extent resulting from (i) Evotec’s negligence or
willful misconduct; (ii) Evotec’s breach of this Agreement; or (iii) Evotec’s (or any of its licensee’s (including Evotec Customers) or transferee’s) use of the Assay Development Services Intellectual Property or
Foundation Background Intellectual Property as set forth in Section 10(h)(ii) of this Agreement (but only to the extent such claim does not result from, or arise out of, an action for which the Foundation is obligated to indemnify the
Foundation pursuant to Section 18(a) of this Agreement). For clarity, the Parties hereby agree that the parenthetical clause in the immediately preceding sentence is not intended to obviate or otherwise limit the possibility that both
Evotec and the Foundation may be determined to be joint tort-feasors and, therefore, share liability. 

  

	 	(c)	Limitation on Damages. NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT, NEITHER PARTY NOR ITS AFFILIATES WILL BE LIABLE TO THE OTHER PARTY OR ITS
AFFILIATES FOR ANY CONSEQUENTIAL, SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR EXEMPLARY DAMAGES OR OTHER SIMILAR OR LIKE DAMAGES (INCLUDING LOSS OF PROFITS) UNDER THIS AGREEMENT EVEN IF SUCH PARTY OR AFFILIATE HAS BEEN ADVISED OF THE POSSIBILITY OF
SUCH DAMAGES; PROVIDED, THAT, NOTHING IN THIS AGREEMENT SHALL EXCLUDE OR LIMIT THE LIABILITY OF EITHER PARTY FOR (I) A BREACH OF SECTION 11 OF THIS AGREEMENT, (II) DEATH OR PERSONAL INJURY OR (III) FRAUD. 

 

	 	(d)	Indemnity Amounts. The Parties hereby agree that any amounts owing pursuant to a Party’s express indemnity obligations under this Agreement shall not be
subject to the limitation on damages restrictions set forth in Section 18(c) of this Agreement. 

  

	19.	Force Majeure. If either Party’s (a) performance of this Agreement or (b) discharge of any of such Party’s obligations under this Agreement
(except for the payment of any sum of money) is prevented, restricted or interfered with by reason of any circumstances beyond the reasonable control of such Party (such as government action, war, fire, explosion, flood, strike, lockout, embargo or
act of God) then such Party shall, upon giving prompt notice in writing to the other Party, be excused from such performance or discharge to the extent, and for the duration, of such prevention, restriction or interference. Any payment obligations
relating to periods of excused performance or discharge shall also be excused and any advance payments for periods of excused performance or discharge shall be refunded or credited. If any of the circumstances 

 

 34 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	 	
described in this Section 19 prevail and a Party’s excused performance or discharge extends for a continuous period of more than ninety (90) days, the Parties shall enter
into good faith discussions with a view to alleviating its effects, or to agreeing upon such alternative arrangements as may be fair and reasonable in view of all of the circumstances. The Parties acknowledge and agree that nothing in this
Section 19 shall prevent a Party from exercising its rights under Section 14 of this Agreement at any time. 

  

	20.	Alternative Dispute Resolution. If a dispute arises out of or relates to this Agreement, or breach thereof, the Parties agree first to try in good faith to
settle such dispute, failing which such dispute shall be settled by a single arbitrator in an arbitration in New York, NY administered by JAMS under its Comprehensive Arbitration Rules and Procedures. The Parties shall instruct the arbitrator that
the prevailing party of any dispute (as determined by the arbitrator) shall be awarded the reasonable attorneys’ fees, costs and other expenses incurred by the prevailing party in the course of the arbitration of such dispute. The award
rendered by the arbitrator shall be final and binding on the Parties, and judgment on the award may be entered in any court having jurisdiction thereof if reasonably necessary for enforcement. The Parties agree that, notwithstanding anything to the
contrary in such rules, any and all such proceedings shall be confidential. 

  

	21.	Assignment. Evotec may not assign this Agreement without the prior written consent of the Foundation, except to an entity (a) that acquires all or
substantially all of the business of Evotec (whether by sale of assets or stock or by merger) and (b) who agrees, in writing, to assume Evotec’s obligations under this Agreement. Evotec hereby agrees that any entity that acquires all or
substantially all of the business of Evotec (whether by sale of assets or stock or by merger) shall (i) acquire Evotec’s interest in Evotec Background Intellectual Property and (ii) agree, in writing, to assume Evotec’s
obligations under this Agreement. The Foundation may assign this Agreement so long as the assignee expressly assumes in writing the Foundation’s obligations in this Agreement. 

 

	22.	Incorporation of Appendices, Supplements and Exhibits; Entire Agreement; Amendment. The appendices, supplements and exhibits identified in this Agreement are
incorporated herein by reference and made a part hereof. If anything in any appendix, supplement or exhibit attached to this Agreement or any notice, invoice or other document delivered by a Party under this Agreement conflicts with any terms
or conditions set forth in the body of this Agreement, the terms and conditions set forth in the body of this Agreement shall control. This Agreement constitutes the entire agreement among the Parties relating to the Services and all prior
understandings and agreements relating to the Services are superseded hereby. This Agreement may not be amended except by a document signed by the each of the Parties. 

 

	23.	No Waiver. Any failure of a Party to enforce any provision of this Agreement shall not be deemed a waiver of its right to enforce such provision on any
subsequent occasion. No waiver of any provision of this Agreement shall be valid unless it is in writing and is executed by the Party against whom such waiver is sought to be enforced. A waiver by any of the Parties of any provision of this
Agreement will not be construed to be a waiver of any succeeding breach thereof or of any other provision of this Agreement. 

  

	24.	Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law. In the
event a court of competent jurisdiction holds any provision of this Agreement to be invalid, such holding shall have no effect on the remaining provisions of this Agreement, and they shall continue in full force and effect. 

 

	25.	Interpretation; Headings. The word “including” shall mean “including without limitation”. All pronouns and any variations thereof refer to
the masculine, feminine or neuter, singular or plural, as the context may require. All terms defined in this Agreement in their singular or plural forms have correlative meanings when used herein in their plural or singular forms, respectively.
Headings used in this Agreement are for convenience of reference only and are not intended to influence the interpretation hereof. 

  

 35 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

	26.	Governing Law. This Agreement shall be governed by and construed in accordance with the domestic laws of the State of New York without giving effect to any
choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of New York. 

 

	27.	No Strict Construction. The Parties have participated jointly in the negotiation and drafting of this Agreement. In the event of an ambiguity or question of
intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties, and no presumption or burden of proof shall arise favoring or disfavoring any of the Parties by virtue of the authorship of any of the
provisions of this Agreement. 

  

	28.	Counterparts. This Agreement may be signed, including by facsimile signature, in two or more counterparts and each such counterpart will constitute an original
document and such counterparts, taken together, will constitute the same instrument. 

  

	29.	Termination of Certain Services Agreements. 

  

	 	(a)	Services Agreement Terminating as of the Original Effective Date. The Parties hereby agree that effective as of the Original Effective Date each of (i) that
certain Services Agreement, dated as of April 24, 2006, between the Foundation and Evotec AG and (ii) that certain Second Amended and Restated Services Agreement, dated as of September 1, 2007, between the Foundation and Evotec UK
shall terminate in accordance with their respective terms. 

  

	 	(b)	Services Agreement Terminating as of the Effective Date. The Parties hereby agree that effective as of the Effective Date each of (i) that certain Services
Agreement, dated as of June 1, 2006, between the Foundation and Evotec AG and (ii) that certain Services Agreement, dated as of August 1, 2006, between the Foundation and Evotec AG shall terminate in accordance with their respective
terms and be superseded by this Agreement. 

 * * * * * 

 

 36 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

 In witness to the foregoing, the Parties have executed this Amended and Restated Services
Agreement as of the date first written above. 
 FOUNDATION: 

 

			
	CHDI FOUNDATION, INC.
		
	 By:
	 	 /s/    ROBI
BLUMENSTEIN

		 	CHDI Management, Inc. as authorized
		 	agent of CHDI Foundation, Inc.
		 	by Robi Blumenstein, President—CHDI Management

EVOTEC: 
  

					
	 EVOTEC AG
	 	
			
	By:	 	 /s/    MARK ASHTON
	 	 /s/    KLAUS
MALECK

	 Name:
	 	Mark Ashton	 	Klaus Maleck
	 Title:
	 	EVP Business Development	 	CFO

  

			
	EVOTEC (UK) LTD.
		
	 By:
	 	 /s/    M. POLYWKA

	Name:	 	Mario Polywka
	 Title:
	 	COO

  

 37 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

 Appendix A to Services Agreement 

(Compound Data and Compound Specification Guidelines) 

Unless otherwise specified by the Foundation Services Manager (any such request to be documented in the applicable Steering Committee
meeting minutes), the Parties hereby agree that the following Compound Data and Compound Specifications shall be applicable to each Compound that is the subject of a Project under this Agreement. 

 

	1.	Compound Purity. The Parties hereby acknowledge that Compound purity is dependent on the chemical structures synthesized under this Agreement. Unless otherwise
specified by the Foundation Services Manager (any such request to be documented in the applicable Steering Committee meeting minutes), Evotec shall undertake to procure Compounds and synthesize Compounds with purities greater than or equal to 95%.
Upon the request of the Foundation Services Manager (such request to be documented in the applicable Steering Committee meeting minutes), Evotec shall undertake to purify Compounds procured by Evotec under this Agreement to have purities greater
than or equal to 95%. 

  

	2.	Analytical Methods. Unless otherwise specified by the Foundation Services Manager (any such request to be documented in the applicable Steering Committee meeting
minutes), all Compounds shall be analyzed using LCMS. Evotec shall (i) conduct NMR sampling of 10% of all library and procured Compounds and (ii) conduct NMR sampling of 100% of single synthesized Compounds. 

 

	3.	Compound Format. Unless otherwise specified by the Foundation Services Manager (any such request to be documented in the applicable Steering Committee meeting
minutes), all Compounds will be supplied as single Compounds in bar-coded amber vials as dry powder. 

  

	4.	Compound Weight. Unless otherwise specified by the Foundation Services Manager (any such request to be documented in the applicable Steering Committee meeting
minutes), all Compounds shall be delivered to the Foundation in a quantity equal to an average weight of (a) 20 milligrams for Compounds subject to Compound Synthesis Services and (b) 50 milligrams for Compounds subject to Compound
Procurement Services. 

  

 38 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934. 

 Appendix B to Services Agreement 

(Descriptions of Certain Evotec Background Intellectual Property) 

Part
1—EVOscreen® Technology 

Automated ultra high throughput screening systems comprising robotic, miniaturized, liquid handling systems, confocal fluorescence
detection and signal processing systems, confocal beam scanning, M2N and Nanocarrier storage units, development stations, associated software, source codes, generic assay miniaturization and miniaturized generic assay principles and technologies,
generic labeling technology and labeling procedures and specific substrates. 
 Part 2—FCS+plus Technology 

Fluorescence spectroscopy, including but not limited to, confocal spectroscopy, characterized by the availability of different parameters
for quantifying specific compound-target interactions. This minimizes assay optimization time as the detection system that delivers the best signal can be chosen. In addition, it enables mechanistic characteristics such as binding constants,
catalytic constants, on/off rates and conformational changes to be quantitatively determined. The ability to collect multiple data points per measurement not only provides an internal control but also contributes to high quality by enabling, rapid,
multi-parameter evaluation of compound/target interactions. 
 Part 3—Miniaturisation Technology 

Evotec’s confocal fluorescence spectroscopy technique measures molecular interactions in detection volumes of
less than one femtoliter (10-15 litre). They eliminate
disturbing influences including innerfilter effects, sample autofluorescence, and surface effects, and are ideally suited for 1 μl miniaturized assay formats, thus minimizing the amounts of required targets, compounds, and reagents and
reducing wastage. 
 Part
4—OperaTM Technology 

Opera is an automated imaging reader. The Opera is based on an inverted microscope, equipped with a motorized sample stage. This allows
for fully automated imaging of a multitude of samples provided in multiple positions on a sample carrier. 
  

 39 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the 
 Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 

of the Securities Exchange Act of 1934.SHARE PURCHASE AGREEMENT

Table of Contents

  

 
 Exhibit 4.19 

 
 EVOTEC AG
· DIL LIMITED 

& 

RESEARCH SUPPORT INTERNATIONAL PRIVATE LIMITED

 SHARE PURCHASE AGREEMENT 

Dated: August 6, 2009 
  

 
  
  

 
  

Table of Contents

 TABLE OF CONTENTS 

 

					
	 INDEX OF DEFINED TERMS
	  	3
	 SECTION I.    PURCHASE AND SALE OF SHARES
	  	6
	 CLAUSE 1.01
	  	SALE AND PURCHASE	  	6
	 CLAUSE 1.02
	  	PURCHASE PRICE	  	6
	 CLAUSE 1.03
	  	CLOSING	  	7
	 SECTION II.    PAYMENTS, COSTS AND TAXES
	  	10
	 CLAUSE 2.01
	  	MANNER OF PAYMENTS	  	10
	 CLAUSE 2.02
	  	TRANSACTION COSTS, SEPARATION COSTS AND
TAXES	  	10
	 SECTION III.    REPRESENTATIONS
	  	11
	 CLAUSE 3.01
	  	MUTUAL REPRESENTATIONS AND WARRANTIES	  	11
	 CLAUSE 3.02
	  	SELLER AND COMPANY REPRESENTATIONS	  	11
	 CLAUSE 3.03
	  	PURCHASER REPRESENTATIONS	  	12
	 SECTION IV.    REMEDIES
	  	13
	 CLAUSE 4.01
	  	RESTITUTION IN KIND; DAMAGES	  	13
	 CLAUSE 4.02
	  	LIMITATIONS	  	13
	 CLAUSE 4.03
	  	EXCLUSIVE REMEDIES	  	14
	 CLAUSE 4.04
	  	DUTY TO INFORM	  	14
	 CLAUSE 4.05
	  	BREACH BY PURCHASER	  	15
	 SECTION V.    CONFIDENTIALITY
	  	16
	 CLAUSE 5.01
	  	CONFIDENTIAL INFORMATION DEFINED	  	16
	 CLAUSE 5.02
	  	DISCLOSURE	  	16
	 CLAUSE 5.03
	  	CONFIDENTIALITY OBLIGATIONS	  	16
	 CLAUSE 5.04
	  	OWNERSHIP	  	17
	 CLAUSE 5.05
	  	REMEDIES	  	17
	 SECTION VI.    MISCELLANEOUS
	  	18
	 CLAUSE 6.01
	  	INTERPRETATION AND CONSTRUCTION	  	18
	 CLAUSE 6.02
	  	GOVERNING LAW, DISPUTE RESOLUTION AND
JURISDICTION	  	18
	 CLAUSE 6.03
	  	NOTICES	  	19
	 CLAUSE 6.04
	  	WAIVERS	  	20
	 CLAUSE 6.05
	  	ENTIRE AGREEMENT	  	20
	 CLAUSE 6.06
	  	FORCE MAJEURE	  	20
	 CLAUSE 6.07
	  	FURTHER ASSURANCES AND NO OBSTRUCTION OF PURPOSE
	  	21
	 CLAUSE 6.08
	  	COUNTERPARTS	  	21
	 CLAUSE 6.09
	  	AMENDMENTS	  	21
	 CLAUSE 6.10
	  	ASSIGNMENT, DELEGATION AND SUB-CONTRACTING	  	21
	 CLAUSE 6.11
	  	SUCCESSORS, ASSIGNS AND THIRD-PARTY
BENEFICIARIES	  	22
	 CLAUSE 6.12
	  	NO PARTNERSHIP OR AGENCY	  	22
	 CLAUSE 6.13
	  	PUBLIC ANNOUNCEMENTS	  	22
	 CLAUSE 6.14
	  	NO ADVERSE CONSTRUCTION	  	22
	 CLAUSE 6.15
	  	SEVERABILITY	  	22
	 CLAUSE 6.16
	  	INTERIM MANAGEMENT	  	22
	 SCHEDULE I: COMPANY PARTICULARS
	  	24
	 SCHEDULE II: POST-CLOSING SHAREHOLDING
	  	25
	 SCHEDULE III: SELLER AND COMPANY REPRESENTATIONS
	  	26
	 SCHEDULE IV: DISCLOSURE LETTER
	  	32

  

 2 

Table of Contents

 INDEX OF DEFINED TERMS 

 

			
	 TERM
	  	 PROVISION

		
	 Act
	  	Clause 1.01(3)
		
	 Agreed Equity Value
	  	Clause 1.02(1)
		
	 Agreement
	  	Recitals (second paragraph)
		
	 Articles
	  	Clause 1.03(2)xi.a)
		
	 Audited Accounts
	  	Schedule III, paragraph 6.1
		
	 Balance Sheet Date
	  	Schedule III, paragraph 7.1
		
	 Bank Loan
	  	Clause 1.02(1)ii
		
	 Best Knowledge
	  	Clause 3.02(2)
		
	 Board
	  	Clause 1.03(2)xi
		
	 Closing
	  	Clause 1.01(2)
		
	 Closing Date
	  	Clause 1.01(2)
		
	 Company
	  	Identification of parties
		
	 Confidential Information
	  	Clause 5.01(1)
		
	 Current Assets
	  	Clause 1.02(1)vii.a)
		
	 Current Liabilities
	  	Clause 1.02(1)vii.b)
		
	 De Minimis Amount
	  	Clause 4.02(2)
		
	 Discloser
	  	Clause 5.01(1)
		
	 Disclosure Letter
	  	Clause 3.02(1)v
		
	 Force Majeure Event
	  	Clause 6.06(1)
		
	 IAS
	  	Clause 1.02(1)vii.a)
		
	 Instrument of Transfer
	  	Clause 1.03(2)iv
		
	 Inter-Company Capex Balances
	  	Clause 1.02(1)iv
		
	 IT Systems
	  	Schedule III, paragraph 12.1
		
	 Liability Cap
	  	Clause 4.02(3)
		
	 Liens
	  	Clause 1.01(3)
		
	 Loss
	  	Clause 4.01(2)
		
	 NWC Adjustment
	  	Clause 1.02(1)vii
		
	 Non-Performing Party
	  	Clause 6.06(1)
		
	 Notional Target Share Value
	  	Clause 1.02(1)
		
	 Ordinary Course of Business
	  	Schedule III, paragraph 6.5.1
		
	 Owned IP
	  	Schedule III, paragraph 10.2
		
	 Preference Share Amount
	  	Clause 1.02(1)iii
		
	 Purchase Price
	  	Recitals (second paragraph)

  

 3 

Table of Contents

			
	 TERM
	  	 PROVISION

		
	 Purchaser
	  	Identification of parties
		
	 RBI
	  	Clause 1.02(1)i
		
	 Recipient
	  	Clause 5.01(1)
		
	 Representations
	  	Clause 1.03(2)i
		
	 Requirement
	  	Proviso to Clause 5.03(1)
		
	 Restated Articles
	  	Clause 1.03(2)xi.c)
		
	 Restitution in Kind
	  	Clause 4.01(1)
		
	 Returns
	  	Schedule III, paragraph 7.6
		
	 Shareholders’ Agreement
	  	Recitals (fourth paragraph)
		
	 Seller
	  	Identification of parties
		
	 Target Shares
	  	Recitals (second paragraph)
		
	 Tax
	  	Clause 4.02(1)v
		
	 Threshold
	  	Clause 4.02(2)

  

 4 

Table of Contents

 SHARE PURCHASE AGREEMENT 

DATED AUGUST 6, 2009 

BY AND BETWEEN 

A. Evotec AG, a company registered under the laws of Germany, with the commercial register of the Lower Court of Hamburg, under
docket number HRB 68223, with its principal place of business at Schnackenburgallee 114, 22525, Hamburg, Germany (“Purchaser”); 

B. DIL Limited, a company registered under the laws of India (corporate identity number L99999MH1951PLC008485), having its
registered office at ‘DIL Complex’, Ghodbunder Road, Thane (West) - 400 610, India (“Seller”); and 

C. Research Support International Private Limited, a company registered under the laws of India (corporate identity number
U74130MH2004PTC145141), having its registered office at ‘DIL Complex’, Ghodbunder Road, Thane (West) - 400 610, India (“Company”). 

WHEREAS, the Company is a private company limited by shares, wholly-owned by the Seller as shown in Schedule I to
this Agreement. 
 AND WHEREAS, the Seller wishes to sell to the Purchaser twenty-five million,
four hundred and ninety-four thousand (25,494,000) issued and fully paid-up equity shares, having a par value of Rs. 2 (Rupees two only) each, in the share capital of the Company (“Target Shares”), against payment by the
Purchaser to the Seller of the purchase price for all the Target Shares (“Purchase Price”), and on and subject to the other terms and conditions specified in this Share Purchase Agreement (“Agreement”). 

AND WHEREAS, the Purchaser wishes to purchase the Target Shares from the Seller against payment of the
Purchase Price and on and subject to the other terms and conditions specified in this Agreement. 
 AND
WHEREAS, the parties have simultaneously with the execution of this Agreement entered into a shareholders’ agreement (“Shareholders’ Agreement”) for the purpose of regulating their relationship in relation
to the Company and regulating the way in which the Company shall be managed after the Purchaser has bought and the Seller has sold the Target Shares in accordance with this Agreement. 

NOW THEREFORE, THE PARTIES AGREE AS
FOLLOWS. 
  

 5 

Table of Contents

 SECTION I.    PURCHASE AND SALE OF SHARES

 Clause 1.01    SALE AND PURCHASE

 (1) On the terms and subject to the conditions set forth in this Agreement, the Seller shall sell, assign and transfer to
the Purchaser, and the Purchaser shall purchase from the Seller all right, title and interest in and to the Target Shares against payment of the Purchase Price. 

(2) The consummation of such sale, assignment and transfer and the payment of the Purchase Price shall be complete and shall be deemed to
be complete in accordance with Clause 1.03 of this Agreement, and only if and when all of the steps and actions specified in Clause 1.03 of this Agreement are completed (“Closing”). The date on which Closing shall occur
(“Closing Date”) shall be August 31, 2009. 
 (3) Any Target Shares, when sold, assigned and transferred
to the Purchaser on the Closing Date pursuant to this Agreement, shall be paid-up to the full extent of their par value, and shall be free and clear of all liens, charges, claims, third party rights and other encumbrances (“Liens”)
thereon, provided that the Target Shares when so sold, assigned and transferred to the Purchaser shall be subject to any restrictions expressly provided for in the Shareholders’ Agreement and such restrictions as affect the transferability of
the Target Shares pursuant to the provisions of Section 
3(1)(iii)(a) of the Companies Act, 1956 (“Act”). 
 Clause
1.02    PURCHASE PRICE 
 (1) The Purchase Price shall be an amount
equivalent to seventy-five (75) percent of the “Notional Target Share Value,” which Notional Target Share Value shall, in turn, be an amount equivalent to seventy (70) percent of the “Agreed Equity Value”
of the Company. For purposes of this Agreement the Agreed Equity Value shall be: 
  

	i.	The Indian Rupee amount that is equivalent to €4,000,000 (four million euro only) as on the Closing Date, which Indian Rupee amount shall be obtained using the
reference rate published by the Reserve Bank of India (“RBI”) on its website (www.rbi.org.in) at 17:30 hours (Indian Standard Time) on the day immediately prior to the Closing Date; 

 

	ii.	Less the amount of the term loan owed by the Company to the Union Bank as shown in the books of the Company on the Closing Date (“Bank Loan”), and
which Bank Loan amount shall be verified and dealt with after the Closing Date in accordance with the provisions of the Shareholders’ Agreement; 

  

	iii.	Less a sum of Rs. 25,000,000 (Rupees twenty-five million only) representing the fully paid-up par value and share premium amount previously received by the Company on
two hundred and fifty thousand (250,000) redeemable preference shares of the Company issued to and held by the Seller as on the Closing Date (“Preference Share Amount”), and which Preference Share Amount shall be verified and
dealt with after the Closing Date in accordance with the provisions of the Shareholders’ Agreement; 

  

	iv.	Less a sum of Rs. 12,486,831 (Rupees twelve million, four hundred and eighty-six thousand, eight hundred and thirty-one only) representing the value of capital
expenditure-related balances owed by the Company to the Seller as on the Closing Date (but not including any current expenditure-related balances owed by the Company to the Seller, such as by way of rental payments, electricity charges, support
service charges and similar recurring charges or current expenditures) (“Inter-Company Capex Balances”), and which Inter-Company Capex Balances shall be verified and dealt with after the Closing Date in accordance with the
provisions of the Shareholders’ Agreement; 

  

	v.	Plus cash and cash equivalents being the aggregate amount shown in the books of the Company on the Closing Date of the following. 

 

	 	a)	Any bank balances; 

  

	 	b)	Plus interest accrued on fixed deposits; 

  

	 	c)	Less bank overdrafts, if any; 

  

 6 

Table of Contents

	vi.	Less any other debt-like items being the amounts shown in the books of the Company on the Closing Date for the following. 

 

	 	a)	Provision for leave encashment subject to actuarial valuation; 

  

	 	b)	Creditors outstanding for greater than one hundred and eighty (180) days; 

 

	 	c)	Accrued performance bonus; and 

  

	 	d)	Other direct taxes; 

  

	vii.	Plus the “NWC Adjustment”, i.e., the positive or negative amount by which the difference between Current Assets (as defined hereafter) and Current
Liabilities (as defined hereafter), as specified in the books of the Company as on the Closing Date, deviates from Rs. 13,894,000 (Rupees thirteen million, eight hundred and ninety-four thousand only), and which NWC Adjustment shall be verified
and dealt with after the Closing Date in accordance with the provisions of the Shareholders’ Agreement. Provided that no NWC Adjustment shall be made if the said difference is less than Rs. 1,390,000 (Rupees one million, three hundred and
ninety thousand only). For purposes of this Agreement: 

  

	 	a)	Current Assets mean the sum of inventories (i.e., all finished product, work in progress, raw materials and other supplies), sundry debtors (i.e., normal
business debtors, including debtors outstanding for a period exceeding six months, and other debtors), income receivable, advances recoverable in cash or in kind or for value to be received and deposits (excluding any rent deposit) as on the Closing
Date, determined in accordance with Indian accounting standards as consistently applied by the Company in the past (“IAS”); and 

  

	 	b)	Current Liabilities means the sum of any sundry creditors (excluding any rent deposit), amounts owed to the Seller (other than the amounts referred to in Clause
1.02(1)iii or Clause 1.02(1)iv above), amounts owed to the Seller’s subsidiary Fermenta Biotech Limited, other expenses payable, customer advances received and statutory dues of the Company as on the Closing Date, determined in accordance with
IAS. 

 (2) It is clarified that 
  

	i.	The Purchase Price = seventy-five (75) percent of the Notional Target Share Value; 

 

	ii.	The Notional Target Share Value = seventy (70) percent of the Agreed Equity Value, and 

 

	iii.	The Agreed Equity Value = (The Indian Rupee equivalent of €4,000,000 as on the Closing Date) less (the Bank Loan) less (the Preference Share Amount) less (the
Inter-Company Capex Balances) plus (cash and cash equivalents) less (any other debt like items) plus (the NWC Adjustment). 

 
Clause 1.03    CLOSING 
 (1) Closing shall take place at the offices of the Company
in Thane, India, at 12:30 p.m. on the Closing Date. 
 (2) In order for Closing to occur, the parties shall complete each of the
following actions and steps on or prior to the Closing Date, in such sequence as may be deemed convenient by the parties; provided that none of the following actions and steps shall be deemed to have been completed unless all of the following
actions and steps have been completed by the Closing Date. It is clarified that failure of any party to meet its obligations or complete Closing as required under this Clause 1.03(2) shall be a material breach of the provisions of this Agreement.

  

	i.	The Company and Seller shall each deliver to the Purchaser, a written confirmation to the effect that (a) the representations and warranties made by each them in
or pursuant to this Agreement (“Representations”) are true, accurate and complete as on the Closing Date, subject to any express terms and conditions relating to such Representations as are contained in this Agreement, and
(b) the Company and Seller are not aware of any matter or thing that is in breach of or inconsistent with any Representation; 

  

 7 

Table of Contents

	ii.	The Company and Seller shall each deliver to the Purchaser certified copies of the minutes recording resolutions of their respective boards of directors authorizing
execution and performance of this Agreement; 

  

	iii.	The Purchaser shall deliver to each of the Seller and the Company certified copies of the minutes recording the resolution of the board of directors of the Purchaser
authorising the execution and performance of this Agreement; 

  

	iv.	The Purchaser and Seller shall jointly fill in the particulars on an instrument of transfer in Form 7B prescribed pursuant to Section 108(1A) of the Act (read with
Rule 5A of the Companies (Central Government’s) General Rules and Forms, 1956) (“Instrument of Transfer”) for the sale of the Target Shares against payment of the Purchase Price; 

 

	v.	The Seller shall procure for purposes of further submission to the RBI, a certificate issued by a qualified chartered accountant in India confirming that the price per
share stated in the Instrument of Transfer is not less than the fair valuation of shares as per the requirements prescribed by the RBI; 

  

	vi.	The Purchaser shall deliver to the Seller for purposes of further submission to the RBI, and to the extent required by the RBI, a declaration to the effect that the
Purchaser is eligible to acquire the Target Shares under the foreign direct investment policy of India and that the existing ‘sectoral limits’ and ‘pricing guidelines’ prescribed by the agencies of the Government of India have
been complied with in this regard, together with a certified copy of the Purchaser’s charter and bylaws and of the minutes recording the resolution of the board of directors of the Purchaser authorising the execution and performance of this
Agreement; 

  

	vii.	The Purchaser shall duly stamp the Instrument of Transfer or cause the Instrument of Transfer to be duly stamped, as specified in Clause 2.02(1), and thereafter, the
Purchaser and Seller shall cause their authorized representatives to each sign such duly stamped Instrument of Transfer; 

  

	viii.	The Purchaser shall deliver the duly stamped and signed Instrument of Transfer to the Company, and the Seller shall simultaneously deliver to the Company all share
certificates (or if no certificates are in existence, letters of allotment) representing the Target Shares; 

  

	ix.	The Purchaser shall pay to the Seller, in accordance with the provisions of Section II of this Agreement, a sum equivalent to the Purchase Price, and provide to the
Seller and the Company evidence of such payment in a form acceptable to the Seller; 

  

	x.	The Purchaser and Seller shall jointly apply to the Company for registration of the Target Shares in the name of the Purchaser; 

 

	xi.	The Company shall convene a meeting of the board of directors of the Company (“Board”) to resolve the following. 

 

	 	a)	Approve the sale, transfer and assignment of the Target Shares by the Seller to the Purchaser and confirm that such sale, transfer and assignment is in accordance with
the articles of association of the Company (“Articles”) and that no fee is payable to the Company on the said transfer; 

  

	 	b)	Direct the Company to register the transfer of the Target Shares to the Purchaser and do all things necessary and incidental thereto, provided that the parties shall
have satisfied their respective obligations specified in the preceding provisions of this Clause 1.03(2); 

  

	 	c)	Recommend that the shareholders of the Company alter the Articles by adopting the restated Articles in accordance with the Shareholders’ Agreement
(“Restated Articles”); 

  

	 	d)	Receive and accept the resignation of Mr. Govind G. Desai, Mr. Satish Varma and Mr. Irfan Bandukwalla as directors of the Company;

  

	 	e)	Recommend the reconstitution of the Board by way of appointment of Dr. Werner Lanthaler, Dr. Mario Polywka and Dr. Klaus Maleck as the directors
nominated by the Purchaser and the continuance of Mr. Krishna Datla and the appointment of Mr. Kunal Kashyap as the directors nominated by the Seller pursuant to and in accordance with the Shareholders’ Agreement and Restated
Articles; and 

  

 8 

Table of Contents

	 	f)	Direct the Company to file necessary statutory forms concerning the adoption of the Restated Articles and change in Board composition subject to the Company’s
shareholders’ approval thereof, pursuant to the provisions of Clause 1.03(2)xii of this Agreement; 

  

	xii.	The Company shall convene a meeting of the shareholders of the Company (which meeting shall be attended by the Purchaser and the Seller or their proxies) to resolve the
following. 

  

	 	a)	Alter the Articles of the Company by adopting the Restated Articles; and 

  

	 	b)	Approve the reconstitution of the Board in accordance with the recommendations of the Board pursuant to Clause 1.03(2)xi of this Agreement; 

 

	xiii.	The Company shall, pursuant to the Board’s direction pursuant to Clause 1.03(2)xi of this Agreement, register the sale, transfer and assignment of the Target
Shares by the Seller to the Purchaser in its books, including its register of share transfers and register of members, and shall record the name of the Purchaser as the owner of the Target Shares, and shall either, by a duly authorized person,
certify the Instrument of Transfer in accordance with Section 113 of the Act to state that a certificate for the Target Shares has been lodged with the Company, or in the alternative, endorse the share certificates for the Target Shares to show
the Purchaser as the owner of the Target Shares, and the Company shall thereafter either provide the certified Instrument of Transfer or, in the alternative, provide the duly endorsed share certificate for the Target Shares to the Purchaser.

 (3) Without prejudice to the provisions of Clause 1.03(2), the parties shall take all measures necessary to
ensure that all the actions and steps specified in Clause 1.03(2) are initiated and completed by the Closing Date. It is understood between the parties that the absence of a non-material closing item as specified in Clause 1.03(2) shall not delay
the Closing. The party responsible for such closing item shall be obligated to perform such closing item without undue delay. 

(4) Upon completion of all the actions and steps specified in Clause 1.03(2) of this Agreement, the Seller will have sold, assigned and
transferred and be deemed to have sold, assigned and transferred to the Purchaser complete, good and valid title in and to the Target Shares free and clear of all Liens thereon, provided that the Target Shares when so sold, assigned and transferred
to the Purchaser shall be subject to any restrictions expressly provided for in the Shareholders’ Agreement and such restrictions as affect the transferability of the Target Shares pursuant to the provisions of Section 3(1)(iii)(a) of the
Act. 
 (5) Upon completion of all the actions and steps specified in Clause 1.03(2) of this Agreement, the Purchaser shall own
and hold seventy (70) percent of the entire issued and paid-up equity share capital of the Company and the Seller shall own and hold the remaining thirty (30) percent of the entire issued and paid-up equity share capital of the Company, as
further specified in Schedule II, and such ownership and holding shall be subject to their respective further obligations under this Agreement and the Shareholders’ Agreement. 

(6) Within such period as is prescribed under the Act, the Company shall complete all filings and registrations with the Registrar of
Companies as are required to be completed pursuant to Clause 1.03(2) of this Agreement. Following the Closing Date, the Seller shall file such forms regarding the sale, assignment and transfer of the Target Shares as may be required by the RBI and
shall be entitled to submit the documents provided by the Purchaser pursuant to the provisions of Clause 1.03(2)v and Clause 1.03(2)vi. 
  

 9 

Table of Contents

 SECTION II.    PAYMENTS, COSTS AND TAXES

 Clause 2.01    MANNER OF PAYMENTS 

 (1) Any payments owed to a party pursuant to this Agreement or the Shareholders’ Agreement shall be made through normal
banking channels, free and clear of costs and charges in immediately available funds to the bank account of the concerned specified below. 
  

	i.	For payments to the Seller: DIL Ltd., “DIL Complex,” Majiwada, Ghodbunder Road, Thane 400 610, India, account number 231-0500705-0 with Standard Chartered
Bank, 90 M. G. Road, Fort, Mumbai 400 001, India, SWIFT Code SCBLINBB; 

  

	ii.	For payments to the Purchaser: Evotec AG, Schnackenburgallee 114, 22525 Hamburg, Germany, account number: 611 000 1 with Deutsche Bank AG, Adolphsplatz 7, 20079
Hamburg; Swift code DEUTDEHHXXX ; and 

  

	iii.	For payments to the Company: Research Support International Pvt. Ltd., “DIL Complex,” Majiwada, Ghodbunder Road, Thane 400 610, India, account number
549701010050119 with Union Bank of India, Ghodbunder Road Branch, Solitaire Tower, Ground Floor, Ghodbunder Road, Chitalsar, Manpada, Thane (West) 400 607, India, SWIFT Code UBININBBGHT. 

(2) Any payments made to a party pursuant to this Agreement or the Shareholders’ Agreement shall be deemed made as soon as the
payment is credited to the account of that party specified in this Clause 2.01. 
 Clause
2.02    TRANSACTION COSTS, SEPARATION COSTS AND TAXES 

(1) All applicable stamp duties arising pursuant to this Agreement or Shareholders’ Agreement, including any stamp duty payable on
this Agreement, the Instrument of Transfer, or the Shareholders’ Agreement, shall be borne by the Purchaser. 
 (2) The
Seller shall bear any tax on capital gains levied or payable on the sale of the Target Shares. 
 (3) In connection with the
sale, transfer, and assignment of the Target Shares, the Seller shall bear the actual separation costs associated with the separation of the Seller’s information technology systems from the Company, provided that the costs so borne by the
Seller shall not exceed an Indian Rupee amount equivalent to €35,000 (thirty-five thousand Euro). 
 (4) Except as
specified above in this Clause 2.02, all other costs and expenses incurred by or on behalf of the parties in connection with the negotiation, preparation and execution of this Agreement shall be borne by the party incurring such expenses on its own
account. 
  

 10 

Table of Contents

 SECTION III.    REPRESENTATIONS

 Clause 3.01    MUTUAL REPRESENTATIONS AND
WARRANTIES 
 Each party represents and warrants to the other parties as follows. 

(1) Such party has all requisite power and authority to enter into and perform its obligations under this Agreement. 

(2) Such party has taken all actions, obtained all regulatory, corporate and contractual authorizations, and submitted all notices or
filings required to be submitted, for such party to validly enter into this Agreement and perform all its obligations under this Agreement. 

(3) The execution and delivery of, or the performance of obligations under, this Agreement do not violate or conflict with any statute,
rule, regulation, directive, other law, judgment, order, decree or award applicable to such party or to any provision of such party’s constituent documents, or any agreement, contract, promise, covenant, undertaking, representation or warranty,
applicable to or made by such party. 
 (4) This Agreement constitutes legal, valid and binding obligations on such party
enforceable against such party in accordance with its terms. 
 (5) Each of the representations and warranties contained in this
Agreement are separate and independent and shall not be qualified or limited by any reference to any other representation or warranty, or any other provision of this Agreement. 

Clause 3.02    SELLER AND COMPANY
REPRESENTATIONS 
 (1) The Seller and Company hereby represent and warrant to the Purchaser, that each
Representation set out in Schedule III to this Agreement is true and correct as on the date of this Agreement and the Closing Date. Provided that: 
  

	i.	any Representation made expressly as of a specific date will be true and correct as of that specific date only; 

 

	ii.	a Representation that addresses any specific circumstances or facts does not allow recourse to a general Representation; 

 

	iii.	each Representation is separate and independent and, save as expressly provided to the contrary in Clause 3.02(1)iv below, shall not be qualified by inference from or
read with any other Representation or any other term of this Agreement; 

  

	iv.	each Representation is given subject to the limitations expressly set out in this Agreement, including the limitations set out in Clause 4.02 of this Agreement and, in
view of these limitations, the Representations shall not constitute, in whole or in part, a guarantee concerning the quality of the Company’s assets, business, personnel, or operations; and 

 

	v.	the Representations are given subject to the conditions, clarifications and qualifications set out in the disclosure letter provided by the Company and Seller to the
Purchaser and attached as Schedule IV to this Agreement (“Disclosure Letter”). 

 (2)
Subject to the provisions of Clause 3.02(1), the Seller and Company acknowledge that the Purchaser, in entering into this Agreement, is relying on the Representations. The Seller and Company further acknowledge that where any Representation is
stated to be made on the basis of the Seller’s or the Company’s “Best Knowledge,” the Purchaser shall be entitled to regard such Representation as made after the exercise of reasonable diligence by such party. 

 

 11 

Table of Contents

 Clause 3.03    PURCHASER
REPRESENTATIONS 
 The Purchaser hereby represents, warrants and covenants to the Seller, that the Purchaser
has, and will have as required by this Agreement, liquid funds that are not committed for any other purpose, in an amount sufficient to cover its financial obligations arising under the terms of or pursuant to this Agreement, including with respect
to the payment of the Purchase Price, of all other sums related to the purchase of the Target Shares and any amounts payable by the Purchaser pursuant to the Shareholders’ Agreement. 

 

 12 

Table of Contents

 SECTION IV.    REMEDIES 

Clause 4.01    RESTITUTION IN KIND;
DAMAGES 
 (1) If and to the extent any of the Representations are incomplete, incorrect or misleading, or if
the Seller or Company fails to perform, or commits a breach in the performance of their respective obligations or covenants under this Agreement, then the Seller shall put the Purchaser or in the Purchaser’s equitable discretion, shall put the
Company, within a period of forty-five (45) working days of written notice by the Purchaser of such breach or misrepresentation, in such position as the Purchaser or the Company (as the case may be) would have been, had the relevant
Representation been complete, correct and not misleading or had the relevant obligation or covenant been performed in full as required by the provisions of this Agreement (“Restitution in Kind”). 

(2) If Restitution in Kind as contemplated in Clause 4.01(1) is not permitted or is impossible by the nature of the breach or
misrepresentation attributable to the Seller (or attributable to the Company prior to the Closing Date), or if and to the extent the Seller or Company fails to provide Restitution in Kind within the period set forth in Clause 4.01(1), and the
Purchaser or Company suffers any loss, liability, settlement payment, fine, fee, penalty, cost, charge, expense or other damage (“Loss”) after the Closing Date as a direct result of such breach or misrepresentation attributable to
the Seller (or attributable to the Company prior to the Closing Date), then the Seller shall pay monetary damages to the Purchaser for the Loss suffered or, at the Purchaser’s equitable discretion, to the Company, subject always to the
provisions of Clause 4.02. 
 (3) Notwithstanding the provisions of Clause 4.01(1), it is clarified that if Restitution in Kind
is fully impossible or not permitted, monetary damages shall substitute for Restitution in Kind entirely; otherwise, monetary damages may only be claimed to the extent Restitution in Kind is impossible or not permitted. 

Clause 4.02    LIMITATIONS 

(1) Notwithstanding anything contained in any other provision of this Agreement or the Shareholders’ Agreement or the Articles or
Restated Articles, the Purchaser shall not be entitled to any claim for breach of any covenant or for any misrepresentation or Loss if and to the extent that the matter to which the claim relates: 

 

	i.	is reflected in the Company’s financial statements and the supporting accounting records by means of any specific liability, accrual or depreciation to the extent
accepted by the Company’s auditors; 

  

	ii.	without prejudice to the rights of any party under or pursuant to any policy of insurance under which such party is a beneficiary, entitles the Purchaser or, after the
Closing Date, the Company to receive payment from any third party for such matter; 

  

	iii.	has been directly caused by either the Purchaser or, after the Closing Date, the Company; 

 

	iv.	results in a benefit to the Purchaser or, after the Closing Date, to the Company, whereby all such benefits received or receivable in connection with the same matter
shall be taken into account; 

  

	v.	results from, or its consequences are directly increased by, the passing of, or any change in, after the date of this Agreement, any law, statute, ordinance, rule,
regulation, or administrative practice of any government, governmental department, agency or regulatory body, including by way of any increase in the rates of any tax, duty, cess, surcharge, levy, penalty or interest thereon
(“Tax”), or the imposition of any Taxes not in effect on the Closing Date, or the withdrawal of any relief from Taxes or any Tax scheme or benefit in effect on the date of this Agreement. 

Provided that where it is subsequently determined that the Purchaser or the Company has received any amount from another party in respect of a claim to
which the Purchaser is not entitled pursuant to the foregoing provisions of this Clause 4.02(1), the Purchaser, or the Company, as the case may be, shall refund such amounts to such other party forthwith and on first demand by such other party.

  

 13 

Table of Contents

 (2) No liability shall arise for the Seller pursuant to this Agreement unless and until an
individual claim against the Seller exceeds Rs. 500,000 (Rupees five hundred thousand only) (“De Minimis Amount”) and the aggregate amount of all such individual claims exceeds Rs. 2,000,000 (Rupees two million only)
(“Threshold”). If the De Minimis Amount and the Threshold are exceeded, the Purchaser shall be entitled to claim the entire amount, and not only the amount exceeding the De Minimis Amount and exceeding the Threshold. 

(3) The aggregate liability of the Seller under or in relation to this Agreement together with the aggregate liability of the Seller
under the Shareholders’ Agreement shall not exceed Rs. 35,000,000 (Rupees thirty-five million only) (“Liability Cap”). Provided that the liability of the Seller in respect of the Representations in Schedule III, paragraphs 1
and 2, of this Agreement and in respect to any Tax Representation shall not be subject to such Liability Cap. Provided further that the aggregate liability of the Seller pursuant to Schedule III, paragraphs 1 and 2, of this Agreement shall be capped
at the Purchase Price. 
 (4) The Purchaser shall not be entitled to bring any claim pursuant to this Agreement if the
underlying facts or circumstances to which the claim relates were known, or if there was a grossly negligent lack of knowledge of such underlying facts or circumstances by the Purchaser, prior to entering into this Agreement. Facts and circumstances
that could reasonably be concluded from the Disclosure Letter, as well as facts and circumstances identified in this Agreement (including its schedules) are deemed to be known by the Purchaser prior to entering into this Agreement. The knowledge of
the Purchaser’s managing directors, advisors and those of its employees who were engaged in carrying out the due diligence examination and discussions with the Seller prior to entering into this Agreement shall be imputed to the Purchaser.

 (5) All claims of the Purchaser arising under or pursuant to this Agreement shall be time-barred eighteen (18) months
after the Closing Date, except for any claim of the Purchaser arising from a breach of any Representation relating to environmental matters, which shall be time barred two (2) years after the Closing Date, and except for any claim of the
Purchaser arising from a breach of any Representation relating to a Tax matter, which shall be time-barred nine (9) months after the first assessment concerning such Tax matter has been completed. 

(6) Notwithstanding anything contained in any other provision of this Agreement or the Shareholders’ Agreement or the Articles or
Restated Articles, no party shall be liable to any other party pursuant to or in connection with this Agreement for any special, punitive, exemplary, indirect, incidental or consequential Loss. 

(7) Notwithstanding anything contained in this Agreement, none of the limitations or caps on liability, stipulated in this Clause 4.02 or
elsewhere in this Agreement, shall apply to any claim that arises (or to the extent that it is increased) as a consequence of fraud, fraudulent misrepresentation or a criminal offence by any director, officer or employee of a party. 

Clause 4.03    EXCLUSIVE REMEDIES 

(1) The parties agree that the remedies provided for in this Agreement are the exclusive remedies available to the parties on any matter
arising from or in relation to this Agreement, including any breach of its provisions, and such remedies supersede and replace any other rights or remedies, whether applicable under statute or in equity in respect thereof. 

(2) All remedies under this Agreement shall be cumulative and not alternative, except as expressly provided to the contrary in this
Agreement. 
 Clause 4.04    DUTY TO INFORM

 The Purchaser shall inform the Seller and the Company if any third party sues, or otherwise brings any legal action
against the Purchaser or the Company with respect to the Company or the Target Shares after the Closing 
  

 14 

Table of Contents

 
Date, if and to the extent such suit or legal action would give rise to any claim by the Purchaser against the Seller in the event the Purchaser or Company were unsuccessful in such suit or legal
action. 
 Clause 4.05    BREACH BY PURCHASER

 In the event of any misrepresentation or breach of covenant under this Agreement, by or attributable to the Purchaser, the
provisions of this Section IV shall apply mutatis mutandis as against the Purchaser. 
  

 15 

Table of Contents

 SECTION V.    CONFIDENTIALITY

 Clause 5.01    CONFIDENTIAL INFORMATION
DEFINED 
 (1) For purposes of this Agreement, “Confidential Information” means any
scientific, technical, trade, financial or business information or materials that are either proprietary or not publicly known that any party (“Discloser”) has disclosed or made available or may from time to time disclose or
otherwise make available to another party (“Recipient”) in connection with or pursuant to this Agreement or the Shareholders’ Agreement. Without prejudice to the generality of the foregoing, Confidential Information includes
the provisions of this Agreement, the Shareholders’ Agreement and information and materials related to any activities of the Discloser whether or not such information is marked or identified as confidential or proprietary. 

(2) Notwithstanding anything contained in Clause 5.01, Confidential Information shall not include information that: 

 

	i.	at the time of disclosure, is known publicly or thereafter becomes known publicly through no fault attributable to the Recipient; 

 

	ii.	becomes available to the Recipient from a third party that is not legally prohibited from disclosing such information, provided such information was not acquired from
the Discloser; 

  

	iii.	was developed by the Recipient independently of information obtained from the Discloser; 

 

	iv.	was already known to the Recipient before receipt from the Discloser, as shown by the Recipient’s prior written records; or 

 

	v.	is released with the prior written consent of the Discloser. 

Clause 5.02    DISCLOSURE 

(1) A disclosure of Confidential Information made by or on behalf of the Discloser, including by its employees, agents, consultants,
affiliates or associates, as well as disclosure by any means (whether written or oral) or through any medium, and any disclosure made prior or subsequent to the date of this Agreement shall be deemed to be a disclosure of Confidential Information
for purposes of this Agreement. 
 (2) Each Discloser hereby represents, warrants and covenants that it is entitled to and will
be entitled to disclose all Confidential Information disclosed pursuant to or in connection with this Agreement or the Shareholders’ Agreement. 

Clause 5.03    CONFIDENTIALITY OBLIGATIONS 

(1) The Recipient hereby covenants to do each of the following with respect to the Confidential Information for such period as such
Confidential Information is not publicly known. 
  

	i.	Keep all Confidential Information in strict confidence, with at least the same level of care as it applies to keeping its own personal, financial or proprietary
information confidential, and in any event no less than reasonable care to prevent the unauthorized disclosure or use of any Confidential Information; 

  

	ii.	Not use, reverse engineer, decompile, disassemble, modify, change, enhance, create any derivative works from, or otherwise deal in any Confidential Information, except
when the Recipient is required to do so solely in connection with this Agreement or the Shareholders’ Agreement and then only as specified by the Discloser; 

 

	iii.	Not disclose any Confidential Information to any other persons or entities except persons who need access to the Confidential Information in connection with this
Agreement or the Shareholders’ Agreement, and who are bound by equivalent obligations of confidentiality; and 

  

 16 

Table of Contents

	iv.	Notify the Discloser in writing immediately upon discovery of any unauthorized use or disclosure of any Confidential Information and reasonably cooperate with the
Discloser to prevent any unauthorized disclosure or use of the Confidential Information and to mitigate any losses arising from such unauthorized disclosure or use. 

Provided that if by reason of a legal requirement, the order of a judicial or administrative authority or the listing requirements of a recognized stock
exchange on which the securities of the Recipient are publicly traded (“Requirement”), the Recipient is mandated to disclose or publish any Confidential Information of the Discloser, the Recipient shall send the Discloser prior
notice of such Requirement in order to allow the Discloser reasonable opportunity to oppose such process or obtain protective or confidential treatment of such Confidential Information, and to the extent that the Discloser is unable to do so within
the time specified to comply with the Requirement, the Recipient covenants to disclose only that portion of the Confidential Information as is mandated to be disclosed by the Requirement. 

(2) Subject to the provisions of Section IV of this Agreement, the Recipient shall be liable for any breach of its covenants in Clause
5.03(1) by any person to whom any Confidential Information is disclosed or provided by the Recipient, and the Recipient undertakes to take any and all necessary actions, at its own cost and expense, to prevent or remedy such breach. 

(3) Upon receipt of a written request from the Discloser, the Recipient shall cease all use of the Confidential Information and promptly
return to the Discloser all documents and materials of the Discloser that relate to or contain any Confidential Information without retaining copies thereof, except for one (1) copy that may be made and retained by the Recipient solely for
record-keeping and for purposes of assuring continued compliance with its obligations under this Agreement. 

Clause 5.04    OWNERSHIP 

(1) Nothing contained herein shall grant the Recipient any right, title or interest in the Confidential Information of another party,
except the limited right to use the Confidential Information solely for the purposes specified pursuant to and in accordance with this Agreement. 

(2) The Recipient acknowledges and agrees that the Discloser is not making and shall not be deemed to have made any implied
representations or warranties regarding the accuracy or completeness of any Confidential Information, but nothing contained herein shall affect any express representation or warranty made with regard to the accuracy or completeness of any
Confidential Information, including any express statements made with regard to the accuracy or completeness of any Representations. 
 
Clause 5.05    REMEDIES 
 The parties agree that, in addition to any other rights or
remedies available under this Agreement, the Discloser shall be entitled to an injunction restraining any breach or any threatened breach of any obligations under this Section V where such breach or threatened breach is in any way attributable to
the Recipient and to seek specific performance by the Recipient of any obligation under this Section V. 
  

 17 

Table of Contents

 SECTION VI.    MISCELLANEOUS

 Clause 6.01    INTERPRETATION AND
CONSTRUCTION 
 (1) The section and clause headings and captions used in this Agreement are for convenience
and identification only; otherwise, they form no part of this Agreement and do not affect its interpretation or construction. 

(2) References to sections, clauses or schedules without further specification are references to sections, clauses and schedules of this
Agreement. 
 (3) References to this Agreement include all sections, clauses and schedules in this Agreement and all recitals to
this Agreement, as amended from time to time in writing by the parties in accordance with Clause 6.09. 
 (4) Any reference to a
statute or any provision of a statute includes a reference to that statute or provision and any rule, regulation, notification, circular, or direction made or issued pursuant to that statute or provision, as may be from time to time modified or
re-enacted. 
 (5) References to the singular include references to the plural and vice versa. 

(6) Words denoting one grammatical gender include references to all grammatical genders. 

(7) When the word “include” or “including” is used in this Agreement, such use means “include without
limitation” and “including without limitation” respectively. 
 (8) Terms used in this Agreement and not defined
herein, but defined in the Act, shall have the meanings given to such terms in the Act. Terms used in this Agreement and not defined herein, but defined in the Shareholders’ Agreement, shall have the meanings given to such terms in the
Shareholders’ Agreement. Provided that terms used in this Agreement that are defined in this Agreement and are also defined in the Act or the Shareholders’ Agreement, shall have the meanings given to such terms in this Agreement.

 Clause 6.02    GOVERNING LAW, DISPUTE
RESOLUTION AND JURISDICTION 
 (1) The laws of India govern all matters arising
out of or relating to this Agreement, including, its validity, interpretation, construction, performance, and enforcement. 

(2) Except as expressly provided in Clause 5.05 of this Agreement, any dispute arising out of, in relation to or in connection with this
Agreement that the parties cannot settle by mutual negotiations, shall be resolved by binding arbitration in accordance with this Clause 6.02. 

(3) The Seller or Purchaser (but not the Company) may initiate the arbitration proceedings by serving upon the other party (i.e., the
Purchaser or Seller) a notice stating that it desires to have a particular dispute referred to arbitration in accordance with this Clause 6.02, and naming and providing the particulars of one individual that such party designates to act as an
arbitrator for such purpose. A copy of such notice shall be sent to the Company at the same time as it is sent to the other party. 

(4) Within thirty (30) calendar days of receipt of such notice, the other party shall respond by either consenting to the
designation in the notice or by designating a second individual to act as arbitrator and shall, in such case, set out the name and particulars of the second individual so designated in such response. A copy of such response shall be sent to the
Company at the same time as it is sent to the party issuing the request for arbitration. 
  

 18 

Table of Contents

 (5) If the party upon whom a request for arbitration is served (i.e., the Seller or
Purchaser) fails to respond to the request within the thirty (30) calendar days specified in Clause 6.02(4), the arbitrator designated by the party requesting arbitration shall act as the sole arbitrator to arbitrate the dispute. 

(6) If both parties (i.e., the Seller and Purchaser) each designate an arbitrator in accordance with the provisions of this Clause 6.02,
the two arbitrators so designated shall within fifteen (15) calendar days of them both being informed of their designation as arbitrators, jointly appoint a third arbitrator who shall also act as umpire. It is clarified and agreed that the
Company shall not be entitled to designate or appoint an arbitrator. 
 (7) No arbitrator designated or appointed pursuant to
this Clause 6.02 shall be employed by, related to, a shareholder in, or otherwise affiliated with any party or any of their affiliates, directors, representatives or contractors. 

(8) The arbitration proceedings shall be conducted at Mumbai, India, in English, and in accordance with and subject to the provisions of
Indian Arbitration and Conciliation Act, 1996. 
 (9) The arbitral decision and award shall be in writing and in English, and
shall be final and binding on the parties. The arbitral decision and award shall specify the manner in which the parties shall bear the costs and expenses of the arbitration. 

(10) Any party may apply to a court having jurisdiction for an order confirming, or to enforce the arbitral decision and award. Except as
provided in Clause 5.05 of this Agreement, the parties hereby waive any right to other judicial or court action on any matter subject to arbitration hereunder, except suit to confirm or enforce the arbitral decision and award. 

(11) The arbitrators shall not extend, modify or suspend any of the terms of this Agreement. 

(12) A notice of, or request for, arbitration will not operate to stay, postpone or rescind the effectiveness of any demand for
performance. 
 (13) Subject to the provisions of this Clause 6.02, the parties hereby confirm that the courts in Mumbai have
jurisdiction over the parties in connection with this Agreement and to determine any matter arising from or otherwise in connection with this Agreement. 

Clause 6.03    NOTICES 

(1) Any notice, direction or other instrument required or permitted to be given under this Agreement shall be in writing and given by
sending it by recognized courier with acknowledgement of receipt requested, or by facsimile or electronic mail (email) to the addresses specified below, or to such other addresses as have been previously notified by each recipient party to the
others in accordance with the provisions of this Clause 6.03. 
 Purchaser 

Evotec AG, Schnackenburgallee 114, 22525, Hamburg, Germany 

Attention: General Counsel 

Facsimile: +49 40 56081 333 

Email: christian.spiegel@evotec.com 

Seller 

DIL Limited, ‘DIL Complex’, Ghodbunder Road, Thane (West) - 400 610, 

India 

Attention: Company Secretary & Legal Manager 

Facsimile: + 91 22 6798 0999 

Email: srikant.sharma@dil.net 
  

 19 

Table of Contents

 Company 

Research Support International Private Limited, ‘DIL Complex’, Ghodbunder Road, Thane 

(West) - 400 610, India 

Attention: Company Secretary 

Facsimile: + 91 22 6798 0999 

Copy to: The other party, being the Purchaser or Seller, as specified above. 

(2) Any notice, direction or other instrument required or permitted to be given under this Agreement shall be deemed to have been validly
and effectively given to and received by a party (a) if sent by recognized courier with acknowledgement of receipt requested, then on the date of delivery to and acknowledgement of receipt by such party, or (b) if transmitted by facsimile
or by electronic mail, then on the day following the date of transmission. Provided that if the day of receipt specified in the preceding sentence of this Clause 6.03(2) is not a working day in the city or town where the recipient party’s
address is located, the day of receipt shall be deemed to be the next working day in such city or town. 

Clause 6.04    WAIVERS 

(1) The Seller may, by written instrument, extend the time for the performance of any of the obligations or other acts of the Purchaser,
and waive any inaccuracies in the Purchaser’s representations and warranties in this Agreement, or the Purchaser’s performance of any of the obligations, covenants or undertakings set out in this Agreement. 

(2) The Purchaser may, by written instrument, extend the time for the performance of any of the obligations or other acts of the Seller
or Company, and waive any inaccuracies in the Representations, or the Seller’s or Company’s performance of any of their respective obligations, covenants or undertakings set out in this Agreement. 

(3) No failure or delay on the part of any party in exercising any right or remedy under this Agreement shall operate as a waiver of that
or any other right or remedy. 
 (4) No single or partial exercise of any right or remedy under this Agreement shall preclude
any other or a future exercise of that or any other right or remedy. 
 Clause
6.05    ENTIRE AGREEMENT 
 (1) This Agreement contains all the promises,
agreements, conditions and understandings between the parties with respect to the subject matter of this Agreement, and supersedes all prior or contemporaneous promises, agreements, conditions and understandings, whether oral or written, with
respect to such subject matter. 
 (2) Without prejudice to the foregoing, the parties hereby acknowledge that the term sheet
dated June 10, 2009, as amended by the addendum dated July 15, 2009, signed on behalf of the Purchaser and Seller with respect to the subject matter hereof, is hereby terminated and is superseded in its entirety by the provisions of this
Agreement. 
 Clause 6.06    FORCE MAJEURE 

(1) For purposes of this Agreement, “Force Majeure Event” means any act or event that prevents a party
(“Nonperforming Party”), in whole or in part, from performing its obligations under this Agreement, or satisfying any conditions to any other party’s obligations under this Agreement, provided that such act or event is beyond
the reasonable control of and not the fault of the Nonperforming Party, and provided that the Nonperforming Party has been unable to avoid or overcome such act or event by the exercise of due diligence. 

 

 20 

Table of Contents

 (2) Where all of the conditions contained in Clause 6.06(1) are met Force Majeure
Events include each of the following acts or events: an act of God (including flood, drought, earthquake, landslide, hurricane, cyclone, typhoon, epidemic, famine or plague), any shipwreck or plane crash, fire, explosion, riot or civil disturbance,
war, act of public enemy, terrorist act, military action, or any action of a court or government authority, or an industry-wide, region-wide or nationwide strike, work-to-rule action, go-slow or similar labour difficulty. 

(3) If a Force Majeure Event occurs, the Nonperforming Party is excused from such performance as is prevented by the Force
Majeure Event, but only to the extent prevented. 
 (4) When the Nonperforming Party is able to resume performance of its
obligations, it shall immediately give the other parties written notice to that effect and shall resume performance no later than five (5) calendar days after the notice is delivered. 

(5) The relief offered by this Clause 6.06 is the exclusive remedy available to the Nonperforming Party with respect to a Force
Majeure Event. 
 Clause 6.07    FURTHER ASSURANCES
AND NO OBSTRUCTION OF PURPOSE 
 (1) Each party
agrees to execute and deliver all further instruments and documents and to perform all other acts that may be reasonably necessary or expedient to further the purposes of this Agreement. 

(2) Each party will not, directly or indirectly, permit or condone any action or engage in any omission or inaction that might cause any
undertaking or covenant, or any representation or warranty not to be satisfied or fulfilled, including any action or inaction that might cause any undertaking, covenant, representation or warranty not to be true, correct and accurate during the term
of or the term required under this Agreement. 
 Clause 6.08    COUNTERPARTS

 (1) This Agreement may be executed in one or more counterparts, in English, all of which together shall constitute one and
the same instrument. 
 (2) Any party may enter into this Agreement by executing a counterpart, and a delivery by facsimile to
the other parties of a copy of any such executed counterpart shall be deemed to constitute delivery of the original counterpart. 
 
Clause 6.09    AMENDMENTS 
 No amendment of, supplement to or suspension of this
Agreement shall be effective unless it is in writing and duly executed by all the parties to this Agreement. 

Clause 6.10    ASSIGNMENT, DELEGATION AND
SUB-CONTRACTING 
 (1) No party may, without the prior written consent of the other parties,
assign to any other person any of its rights, or delegate or sub-contract to any other person, the performance of any of its obligations arising under or related to this Agreement. Provided that each of the parties shall be entitled to appoint duly
authorized individual representatives that are employees of or directors in such party to exercise such party’s rights and perform such party’s obligations pursuant to this Agreement. 

(2) Any purported assignment, delegation or sub-contracting in violation of or contrary to the provisions of this Clause 6.10 is void.
Where a party delegates or sub-contracts the performance of any of its obligations under or in relation to this Agreement to any other person, after obtaining the prior written consent of the other parties, such party shall remain liable for the
performance so delegated or sub-contracted. 
  

 21 

Table of Contents

 Clause 6.11    SUCCESSORS,
ASSIGNS AND THIRD-PARTY BENEFICIARIES 
 (1) This
Agreement binds and benefits the permitted successors and permitted assigns of each party. 
 (2) Without prejudice to the
provisions of Clause 6.11(1), this Agreement does not confer any enforceable rights or remedies upon any person other than the parties. 
 
Clause 6.12    NO PARTNERSHIP OR AGENCY 

Nothing in this Agreement shall, or shall be deemed to constitute a partnership between the parties or to constitute any party as the
agent or trustee of the other parties for any purpose. 
 Clause
6.13    PUBLIC ANNOUNCEMENTS 
 (1) The parties shall not make or publish
any announcement or press release concerning or connected with this Agreement, without the prior written consent of all parties, unless otherwise required by law. 

(2) Where a party is required, by reasons of the regulations of or listing agreement with any recognized stock exchange on which its
securities are listed for public trading, to publish an announcement or press release concerning or connected with this Agreement, the parties shall agree upon the content of such announcement or press release prior to such publication. 

Clause 6.14    NO ADVERSE CONSTRUCTION 

No provision of this Agreement shall be construed against a party on the ground that it drafted or its agents drafted such provision.

 Clause 6.15    SEVERABILITY 

(1) If any provision of this Agreement should be or become entirely or partly invalid or unenforceable, such invalidity or
unenforceability shall not affect the validity or enforceability of any other provision of this Agreement. 
 (2) Any invalid or
unenforceable provision shall be regarded as replaced by such valid and enforceable provision that as closely as possible reflects the economic purpose that the parties had pursued with the invalid or unenforceable provision. 

Clause 6.16    INTERIM MANAGEMENT 

(1) From the date of this Agreement until the Closing Date, the Company shall conduct its operations, and the Seller shall procure that
the Company shall conduct its operations in the ordinary course of business, consistent with prior practice. 
 (2) The parties
shall further refrain from any actions that may impair, jeopardize or impede Closing, and the Seller and Company shall further refrain from any actions that may result in any Representation being incomplete, incorrect or misleading, provided that
entering into this Agreement and the consummation of the parties’ respective obligations hereunder shall not be regarded as contravening any provision of this clause. In particular, without limitation, the Seller shall not offer the Company or
any shares in the Company, or transfer the Company or such shares to third parties or otherwise solicit, encourage, entertain, initiate or participate in any inquiry, negotiations or discussions in this regard. 

(3) From the date of this Agreement until and including the Closing Date each party shall inform the other without undue delay of any
circumstance or occurrence which could impair, jeopardize or impede the Closing, or render any representation of such party, including the Representations, incomplete, incorrect or misleading. 

[Signature page follows.] 
  

 22 

Table of Contents

 INTENDING TO BE BOUND, the parties have executed
this Agreement on the date first above written. 
  

			
	Signed by Dr. Werner Lanthaler and Dr. Mario Polywka, authorised signatories for, and on behalf of, Evotec AG	 	 )
 )

)

		
	Signed by Mr. Krishna Datla, authorised signatory for, and on behalf of, DIL Ltd.	 	 )
 )

)

		
	Signed by Mr. Satish Varma, authorised signatories for, and on behalf of, Research Support International Pvt. Ltd.	 	 )
 )

)

  

 23 

Table of Contents

 SCHEDULE I: COMPANY PARTICULARS 

AUTHORIZED CAPITAL 

As on the date of this Agreement, the authorized share capital of the Company is Rs. 110,000,000 (Rupees one hundred and ten million
only) divided into fifty-two million, five hundred thousand (52,500,000) equity shares of Rs. 2 (Rupees two only) each, and five hundred thousand (500,000) redeemable preference shares of Rs. 10 (Rupees ten only) each. 

ISSUED AND PAID-UP CAPITAL 

As on the date of this Agreement, the issued and paid-up share capital of the Company is as set out in the table below. 

Issued and Fully Paid-Up Equity Shares 
  

					
	 Name of Shareholder
	  	 Name of Beneficial Holder
	  	Number of Shares Held
	 DIL Ltd.
	  	DIL Ltd.	  	36,419,995
	 Mr. Krishna Datla
	  	DIL Ltd.	  	5
	 Total
	  	36,420,000

 Issued and
Fully Paid-Up Redeemable Preference Shares 
  

					
	 Name of Shareholder
	  	 Name of Beneficial Holder
	  	Number of Shares Held
	 DIL Ltd.
	  	DIL Ltd.	  	250,000
	 Total
	  	250,000

  

 24 

Table of Contents

 SCHEDULE II: POST-CLOSING SHAREHOLDING 

Upon completion of all the actions and steps specified in Clause 1.03(2) on the Closing Date, the issued and paid-up share capital of the
Company shall be as set out in the table below. 
 Issued and Fully Paid-Up Equity Shares 

 

						
	 Name of Shareholder
	  	Number of Shares	  	Percentage Holding	 
	 Evotec AG
	  	25,494,000	  	70	% 
	 DIL Ltd. (including through the beneficial holding of five (5) shares)
	  	10,926,000	  	30	% 
	 Total
	  	36,420,000	  	100	% 

 Issued and Fully Paid-Up
Redeemable Preference Shares 
  

						
	 Name of Shareholder
	  	Number of Shares	  	Percentage Holding	 
	 DIL Ltd.
	  	250,000	  	100	% 
	 Total
	  	250,000	  	100	% 

  

 25 

Table of Contents

 SCHEDULE III: SELLER AND COMPANY REPRESENTATIONS

 The Company and Seller each represent and warrant to the Purchaser that, subject to the provisions of Clause 3.02 the
following statements are true and correct as on the date of this Agreement and as on the Closing Date. 
 1. Company Status, Records and
Share Capital 
 1.1. The certificate of incorporation, memorandum of association and Articles of the Company and the Seller
are in full force and effect. 
 1.2. The Company particulars specified in Schedule I to this Agreement are true and
correct prior to the completion of Closing. 
 1.3. Except as specified in Clause 1.03(2) of this Agreement, no action has been
taken to amend the certificate of incorporation, memorandum of association and Articles of the Company. 
 1.4. The Company has
maintained all corporate records including the register of shareholders, register of transfers, register of directors, register of contracts in which directors are interested and all other registers as are required to be maintained under the Act.

 1.5. The Board meetings and the general meetings of shareholders of the Company have been validly held, in accordance with
the provisions of the Act, and all actions and resolutions relating to each such meeting have been taken and passed in accordance with the provisions of the Act. 

1.6. Stamp duties on the issue of share certificates by the Company have been duly paid and share certificates have been issued in
accordance with the provisions of the Act and the Companies (Issue of Share Certificates) Rules, 1960. 
 1.7. The common seal
of the Company is in safe custody and has been used as prescribed by the Act and the Articles. 
 1.8. The Company has been
sending general meeting notices and annual reports to its members in accordance with the provisions of the Act. 
 1.9. The
Company has not: 
  

	 	1.9.1.	redeemed or repaid any share capital, except as specified in the Disclosure Letter; 

 

	 	1.9.2.	reduced its share capital or passed any resolution for the reduction of its share capital; or 

 

	 	1.9.3.	lent money on the security of shares in itself or of any shares in any affiliate of the Company. 

2. Target Shares 
 2.1.
The Target Shares are fully paid-up, and when sold, assigned and transferred to the Purchaser in accordance with the Agreement will be fully paid-up and free and clear of all Liens thereon, provided that the Target Shares when so sold, assigned and
transferred to the Purchaser shall be subject to any restrictions expressly provided for in the Shareholders’ Agreement and such restrictions as affect the transferability of the Target Shares pursuant to the provisions of
Section 3(1)(iii)(a) of the Act. 
 2.2. The Seller has good and valid title to the Target Shares and is not prohibited
from selling the Target Shares to the Purchaser as contemplated by this Agreement. 
  

 26 

Table of Contents

 3. Solvency and Winding Up 

3.1. To the Best Knowledge of the Company and the Seller, no application has been made to any court and no petition presented or meeting
convened for the purpose of considering a resolution for the winding up of the Company or the Seller. 
 3.2. To the Best
Knowledge of the Company and the Seller, no application for the appointment of any liquidator or receiver for any bankruptcy or insolvency proceedings of the Company or Seller has been made or received. 

3.3. The Company and Seller are not party to any scheme of arrangement or composition with any class of creditors or shareholders of the
Company or Seller. 
 3.4. To the Best Knowledge of the Company and the Seller, no action has been taken or initiated to seize,
take possession of or appoint a receiver and/or manager in respect of any shares in the Company or any assets of the Company or Seller. 

3.5. To the Best Knowledge of the Company and Seller, there exist no circumstances, that could give rise to any of the foregoing events
specified above in paragraph 3 of this Schedule III. 
 4. Regulatory Approvals 

4.1. The Company has or has applied to renew all necessary authorizations, licenses, permits and approvals required to carry on its
business as carried out and at the level of operation carried out, including those relating to the protection of the environment, pollution control and dealings in hazardous materials, subject to the clarifications contained in the Disclosure
Letter. Provided that the Company and Seller make no representation or warranty with regard to any authorizations, licenses, permits and approvals that may need to be changed or obtained as a result of the change in ownership, control or management
of the Company after the Closing Date. 
 4.2. In respect of each of the said authorizations, licenses, permits and approvals
all fees due have been duly paid, and to the Best Knowledge of the Company and Seller all conditions have been duly complied with. 

4.3. The Company has not produced or disposed of any untreated biological waste in its course of business. 

5. Compliance with Laws 

5.1. To the Best Knowledge of the Company and the Seller, the Company has complied with all laws applicable to the business of the
Company. 
 5.2. To the Best Knowledge of the Company and the Seller, the Company has not and none of its officers, agents or
employees, has committed or omitted to do any act or thing, the commission or omission of which is in contravention of any law relating to or having a bearing upon the business or operations of the Company. 

5.3. To the Best Knowledge of the Company and the Seller, the Company has not received any notice specifying that the Company is subject
to any pending or threatened claim incurred or imposed or based upon any provision of law or regulation applicable to the Company, including any environmental law. 

6. Accounts and Financial Statements 

6.1. The audited accounts of the Company up to the year ended March 31, 2009 as well as the accounts for the three (3) months
period ended June 30, 2009 which were under a limited review by the statutory auditors (together the “Audited Accounts”) as provided to the Purchaser give a true and fair view of the assets, liabilities (including contingent or
disputed liabilities) and commitments of the Company and its profits for the relevant financial period. 
  

 27 

Table of Contents

 6.2. Such Audited Accounts have been properly prepared in accordance with IAS and comply
with the requirements of applicable laws in India. 
 6.3. Except as stated in the Audited Accounts, no material changes in the
basis of accounting were made during the financial period covered in the Audited Accounts. 
 6.4. Except as stated in the
Disclosure Letter and the Audited Accounts, the Audited Accounts are not affected by any extraordinary, exceptional or non-recurring items. 

6.5. Except as stated in the Disclosure Letter, between the end date stated in the Audited Accounts and the Closing Date, the Company has
not: 
  

	 	6.5.1.	incurred any debt, liability or obligation for borrowed money, or incurred any other debt, liability or obligation that has not been disclosed to the Purchaser, except
current liabilities incurred in the “Ordinary Course of Business”, i.e., based on decisions, actions or measures relating to the Company or its business as are, by their nature or expected implication, customary for such business,
industry or the Company, or in process or ongoing as on the Closing Date, or consistent with or reasonably expected to arise from the Company’s prior practice, course of dealing or current business plans, or are otherwise required by this
Agreement or the Shareholders’ Agreement; 

  

	 	6.5.2.	given any guarantee of any debt, liability or obligation (whether accrued, absolute, contingent or otherwise) that has not been disclosed to the Purchaser, other than
those given in the Ordinary Course of Business; 

  

	 	6.5.3.	declared dividends or made any other payments or distributions in respect of any of its shares, share options, warrants or other securities of the Company;

  

	 	6.5.4.	permitted any of its assets to be subject to any Lien, except in relation to a vehicle that was acquired under a lease by the Company after March 31, 2009;

  

	 	6.5.5.	acquired, sold, leased or otherwise disposed of or transferred any of its assets, where such transaction has not been disclosed to the Purchaser, other than the vehicle
referred to in paragraph 6.5.4, and transactions undertaken in the Ordinary Course of Business; 

  

	 	6.5.6.	made any capital expenditures or commitment outside the Ordinary Course of Business that has not been disclosed to the Purchaser; 

 

	 	6.5.7.	waived or released any right it has or had over any debt owed to it or written-off as uncollectible any amounts receivable, unless such waiver, release or write-off has
been disclosed to the Purchaser; 

  

	 	6.5.8.	made any other change in any method of accounting or auditing practice; 

  

	 	6.5.9.	written down the value of any work-in-progress; or 

  

	 	6.5.10.	agreed, whether or not in writing, to do any of the foregoing, except as permitted by this Agreement or except in the Ordinary Course of Business.

 7. Taxation 

7.1. All Tax liabilities are disclosed in the books of accounts provided to the Purchaser and are appropriately accounted for and no
change has occurred in respect of such Tax liabilities since March 31, 2009 (“Balance Sheet Date”). 

7.2. The indirect Tax concessions enjoyed by the Company as an export-oriented unit under the currently applicable policy for
export-oriented units in India are not impaired. 
 7.3. Since the date of incorporation of the Company, the Company has paid
all applicable Taxes due and payable, including in respect of income or capital gains earned by the Company, or required to be withheld and paid by the Company, or due and payable in respect of services provided by the Company. 

 

 28 

Table of Contents

 7.4. The Company have been assessed in respect of applicable Taxes, and notices of
assessment have been issued to the Company by the relevant income-tax authorities for all taxation years prior to and including the assessment year 2006-07 and by the relevant sales-tax authorities for all taxation years prior to and including the
financial year ended March 31, 2009. 
 7.5. To the Best Knowledge of the Company and the Seller, there are no actions,
suits, proceedings, investigations, audits or claims (other than claims for refunds) now pending in respect of any Taxes payable by the Company and there are no matters under discussion, audit or appeal with any governmental authority relating to
such Taxes. 
 7.6. The Company has filed or caused to be filed in a timely manner (within any applicable extension periods) all
returns, reports, declarations, statements or forms, including information returns (“Returns”) required to be filed in respect of any Taxes on or prior to the Closing Date, and each such Return is true and complete in all material
respects. 
 8. Loans and Borrowings 

8.1. The Company does not owe any amounts to any person, other than the amounts specified in the Audited Accounts and the Disclosure
Letter, except dues incurred in the Ordinary Course of Business between the date of the Audited Accounts and the Closing Date. Provided that, as stated in paragraph 6.5.4 above, the Company acquired a vehicle under a lease agreement after
March 31, 2009. 
 9. Contracts 

9.1. All current material contracts, covenants or arrangements that have been entered into by the Company are specified in the Disclosure
Letter. The Company does not have any other material outstanding commitments or obligations, unless such commitments or obligations have been incurred in the Ordinary Course of Business. 

9.2. Except as stated in the Disclosure Letter, the Company has not entered into any mortgages, security agreements, pledges, indentures,
guarantees or other contracts relating to the borrowing of money or binding upon any of the properties or assets (real, personal or mixed, tangible or intangible) of the Company. 

9.3. Except as stated in the Disclosure Letter, the Company has not entered into any contract or agreement granting any third party a
Lien on all or any part of the assets of the Company. 
 9.4. All current contracts entered into by the Company are in full
force and enforceable in accordance with their terms and have been duly stamped and registered where applicable. 
 10. Assets

 10.1. All the assets owned by the Company or in respect of which the Company has a right of use, are in the possession of
and under the control of the Company, provided that such possession and control is subject to applicable Liens, licenses and contractual terms identified or otherwise enumerated in the various documents listed in the Disclosure Letter. 

10.2. The Company holds valid licenses, title or ownership rights in respect of the trade marks, logos, trade names, internet domain
names, and other intellectual property licensed to or used by the Company in connection with its business. All registered trade marks, logos and domain names owned by the Company is listed in attachment 10.2 to the Disclosure Letter (“Owned
IP”). Attachment 10.2 to the Disclosure Letter is complete and accurate and such Owned IP is valid and subsisting. To the Best Knowledge of the Sellers and the Company: 

 

	 	10.2.1.	There have been no acts or omissions that would prejudice the rights of the Purchaser to enforce the Owned IP; 

 

 29 

Table of Contents

	 	10.2.2.	The Owned IP is not subject to any security interest, option, mortgage, charge or lien and there are no arrangements or agreements that restrict the disclosure, use or
assignment of the Owned IP by the Company; and 

  

	 	10.2.3.	The Owned IP will not be lost or rendered liable to termination, by virtue of the acquisition of the Target Shares or the performance of this Agreement.

 10.3. To the Best Knowledge of the Sellers and the Company, no party to any license agreement related to
intellectual property used by the Company in its business is in default of such license, and there are no grounds, to the Best Knowledge of the Sellers and the Company on which such licenses might be terminated or in respect of which any disputes
have arisen or are expected to arise. 
 10.4. To the Best Knowledge of the Company and the Seller, none of the operations of
the Company infringes or has in the last two (2) years infringed the rights relating to any intellectual property of any third person and no claim has been made by a third person alleging that the operations of the Company infringe any such
intellectual property rights of a third person or which otherwise disputes the right of the Company to use any intellectual property rights used by the Company. To the Best Knowledge of the Company and the Seller, no third party is at present
infringing the Company’s Owned IP. To the Best Knowledge of the Company and the Seller, the Company has complied with all contractual and legal obligations with regard to the transfer of intellectual property—if any—to its customers.

 10.5. The Company has valid lease or license rights, as the case may be, in respect of real property occupied by the Company,
as shown in the Disclosure Letter. 
 11. Confidential Information and Data Protection 

11.1. Confidential information of, or that has been used by the Company has been kept confidential and has not been disclosed to third
parties except in the Ordinary Course of Business and subject to written confidentiality obligations from the third party. To the Best Knowledge of the Company and the Seller, these confidentiality obligations have not been breached and the Company
has not received any notice alleging the breach of any data protection obligations applicable to the Company. 
 12. Information Technology

 12.1. All information and communications technologies used by the Company (“IT Systems”) are owned by, or
properly licensed, leased or supplied under third party contracts to the Company, including under arrangements for support services between the Seller and the Company subsisting prior to the Closing Date. To the Best Knowledge of the Company and the
Seller, the Company is not in default under any of such third party contracts. 
 12.2. To the Best Knowledge of the Company and
the Seller, there are no circumstances in which the ownership, benefit, or right to use the IT Systems may be lost, or rendered liable to termination, by virtue of the acquisition of the Target Shares or the performance of this Agreement.

 12.3. The IT Systems have been adequate for the needs and fit for the purpose of the Company’s business as carried out
prior to the Closing Date. 
 13. Insurance, Litigation and other Proceedings 

13.1. The Company has obtained and maintains insurance policies relating to the assets, properties, business, operations, employees,
officers or directors of the Company required under law and as specified in the Disclosure Letter. 
  

 30 

Table of Contents

 13.2. To the Best Knowledge of the Company and Seller, there are no actions, suits,
proceedings, claims or investigations pending, or threatened against or affecting the Company before any court, quasi-judicial authority, arbitrator or arbitral tribunal, governmental authority, commission, board, agency or instrumentality, and the
Company is not in default of any order, writ, injunction or decree of any court or other judicial or quasi-judicial department, commission, board, bureau, agency or instrumentality. 

14. Employees 
 14.1. The
Company is not involved in and to the Best Knowledge of the Company and Seller, there are no present circumstances likely to give rise to any labour, industrial or trade dispute or any dispute or negotiation regarding a claim of importance with any
employee, worker or association of trade unions or organisation or body of employees. 
 14.2. To the Best Knowledge of the
Company and the Seller, the Company has not breached any law, regulation or authorisation relating to the health or safety of its employees and has made all payments and obtained all permits, licenses and government authorisations required under
applicable laws, including without limitation under the following statutes: Payment of Gratuity Act 1972, Employees’ State Insurance Act 1948, Employees’ Provident Fund and Miscellaneous Provisions Act, 1952, the Payment of Bonus Act,
1965, Contract Labour (Regulation and Abolition) Act, 1970 and the Minimum Wages Act, 1948. 
 14.3. The Company does not have
any recognized or unrecognized trade unions. 
  

 31 

Table of Contents

 SCHEDULE IV: DISCLOSURE LETTER 

Date: August 6, 2009 
 To: 

Evotec AG 
 Schnackenburgallee 114 

22525, Hamburg 
 Germany 

Sirs, 
 Re: Share Purchase
Agreement (“Agreement”) dated August 6, 2009 by and between Research Support International Private Limited (“Company”), DIL Limited (“Seller”), and Evotec AG (“Purchaser”) 

We refer to the captioned Agreement and wish to record the following preliminary matters in connection with this letter. 

Unless the context otherwise requires, words and expressions defined in the Agreement shall have the same meaning where used in this
letter. 
 This letter, together with its attachments, constitutes the Disclosure Letter referred to in the Agreement and the
parties to the Agreement, by acceptance of this Disclosure Letter, agree that the Company and Seller shall not be jointly or severally liable or otherwise be required to indemnify any other party to the Agreement in respect of any matters disclosed
in or by this Disclosure Letter. 
 All disclosures in this Disclosure Letter are to be taken as relating to each of the
Representations and a party to the Agreement, by acceptance of this Disclosure Letter, agrees that it shall not be entitled to claim that any fact or matter has not been disclosed to it by reason of the fact or matter referred to in this Disclosure
Letter not being specifically related to any particular or particularly numerated or titled Representation, or other clause or provision in the Agreement. 

The information contained herein is not prepared or disclosed with a view to its potential disclosure to third persons, and the Company
and Seller shall not be jointly or severally liable to any person for any matter or liability arising from or connected with the disclosure of information to any third person or the reliance by any third person on any information contained herein.

 Subject to applicable law, this information is disclosed in confidence for the purposes contemplated in the Agreement and is
subject to the confidentiality provisions contained in the Agreement. 
 The Company and Seller make no representation or
warranty, express or implied, nor do they admit any liability with respect to the information disclosed in this Disclosure Letter. 

Where any conflict arises between the contents of this Disclosure Letter and the Agreement, the information contained in this Disclosure
Letter shall prevail unless otherwise expressly stated herein. 
 Subject to the above preliminary matters, the disclosures in
relation to the various paragraphs in Schedule III of the Agreement made by the Company and Sellers are as follows. 
  

 32 

Table of Contents

			
	 Paragraph in Schedule III of
the Agreement
	 	 Disclosure

	 Paragraph 1
	 	 A copy of the current certificate of incorporation and the memorandum of association and Articles of the Company are set out in
attachment 1.1.
  
 Amendments to the memorandum of association and Articles
of the Company that have been carried out prior to the date of this Agreement are set out in attachment 1.3.

		
	 Paragraph 2
	 	A copy of the no-objection certificate received from Union Bank in connection with the dilution of the Seller’s holding in the Company is set out in attachment
2.
		
	 Paragraph 4
	 	 A list of licenses held by the Company is set out in attachment 4.

 
 In addition to the consumer registration license to purchase solvent held by the
Company under its license, solvent storage by the Company is presently done in the Seller’s solvent ‘go-down’, pursuant to a memorandum of understanding dated April 8, 2008 between the Seller and the Company. In this regard, the
Seller holds a solvent storage license no. P/WC/MH/16/258/(P117814), valid up to December 31, 2010.
  

In addition, the Seller, as the parent of the Company holds a factories license (number 64468, Registration No.: Thane / 2(m)(i)/313-9) covering the
premises occupied by the Company, which license is valid through December 2009. A copy of this license is also included in attachment 4.

		
	 Paragraph 6
	 	 A copy of the Company’s March 31, 2009 audited accounts is set out in attachment 6.1.

 
 A list of the Company’s creditors as on August 5, 2009 is set out in
attachment 6.5.1.
  
 A list of bonds and guarantees given by the Company
is set out in attachment 6.5.2;
  
 A list of capital expenditures made
between April 1, 2009 and August 5, 2009 is set out in attachment 6.5.6.
  
 A
list of outstanding term loans of the Company as on August 5, 2009 is set out in attachment 8.1.
  

A list of current agreements is set out in attachments 9.1a, 9.1b and 9.1c.

 
 A list of outstanding intercompany transactions with affiliate entities is set out in
attachment 9.1d.
  
 A list of current charges and liens is set out in
attachments 9.2 and 9.3.

		
	 Paragraph 8
	 	A list of outstanding term loans of the Company as on August 5, 2009 is set out in attachment 8.1.
		
	 Paragraph 9
	 	 A list of current agreements as on August 5, 2009 is set out in attachments 9.1a, 9.1b and 9.1c.

 
 A list of outstanding intercompany transactions with affiliate entities, as on
August 5, 2009, is set out in attachment 9.1d.
  
 A list of charges and
liens as on August 5, 2009 is set out in attachments 9.2 and 9.3.

		
	 Paragraph 10
	 	 A list of changes in the assets of the Company, between April 1, 2009 and August 5, 2009 is set out in attachment 10.1.

 
 A list of trademarks and domain name registrations of the Company as on August 5,
2009 is set out in attachment 10.2.

  

 33 

Table of Contents

			
	 Paragraph in Schedule III of
the Agreement
	 	 Disclosure

		
	 Paragraph 12
	 	 The Company is using the Seller’s IT Systems and its infrastructure facilities for its day-to-day operations.

 
 A list of information and communications technologies used by the Company under third
party contracts is set out in attachment 12 and includes arrangements for support services between the Company and the Seller prior to the Closing Date.

		
	 Paragraph 13
	 	A list of the Company’s insurance policies valid as on August 5, 2009 is set out in attachment 13.1.
		
	 Paragraph 14
	 	Pursuant to sub-section 4(a) of Section 1 of the Contract Labour (Regulation and Abolition) Act, 1970, contract labour registration has not applied to the Company, as the Company
has not previously engaged twenty (20) or more workmen as contract labour.

 Please acknowledge receipt of this
Disclosure Letter by countersigning and returning the attached copy. 
 Sincerely, 

Authorised signatory for and on behalf of: 

Research Support International Private Limited 

DIL Limited 
 Received and Accepted 

Authorised signatory for and on behalf of: 

Evotec AG 
 Attachments: As above 

 

 34

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}]]